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DEVELOPMENT OF AN EX VIVO PULSATILE HEART MODEL OF FUNCTIONAL 
MITRAL REGURGITATION TO FACILITATE POSTERIOR PAPILLARY MUSCLE 




Surgical method of choice for functional ischemic mitral regurgitation (FIMR) is 
debatable, since recurrence of FIMR post-annuloplasty has been reported in significant number 
of cases. Developing an ex vivo pulsatile functional mitral regurgitation (FMR) heart model by 
left ventricular (LV) dilatation can be a favorable option for usage in the primary stages of 
developing new surgical techniques that adjunctively targets the posterior papillary muscle 
(PPM) geometry. Posterior papillary muscle of ex vivo ovine hearts was displaced by 3 different 
sizes of patches to induce LV dilatation and FMR. Mitral regurgitation (MR) flow, LV and 
annular geometry were measured from the dynamic pulsatile flow system before and after patch 
placement. Applying the large patch produced the highest proportion of FMR heart models 
(87.5%, P=0.031). In conclusion, the large patch ex vivo pulsatile heart model demonstrated 
outward displacement of the PPM and significantly produced MR flow. This ex vivo pulsatile 
heart model can be used to facilitate surgical techniques that targets the PPM displacement in 
FMR patients. 
The following phase of our research was aimed to utilize this ex vivo pulsatile heart 
model for PPM geometric studies in FMR with PPM displacement despite normal mitral 
annulus. This scenario mimics post-annuloplasty cases when the annular dilatation was corrected 
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by ring annuloplasty but the underlying LV remodeling was not treated. Sonomicrometry was 
used to evaluate the three-dimensional tethered distances and tethered angles of the PPM due to 
regional LV dilatation. The findings of this study implied that although annular dilatation was 
normalized, the increased PPM displacement outside and away from the mitral ring could 
deteriorate mitral leaflet tethering. The decreased tethering angle of the PPM from the annular 
fibrosa, reflecting the overall anterior mitral leaflet (AML) tethering and AML bending, could be 
used for MR prediction.  
Lastly, the ex vivo pulsatile heart model with PPM lateral displacement and septo-lateral 
annular dilatation was used to facilitate additional subvalvular surgical strategy. Reduction 
annuloplasty was used as the standard FIMR treatment but showed suboptimal results with 
recurrent MR. Post-annuloplasty progression of LV remodeling and papillary muscles 
displacement could increase leaflet tethering. Annuloplasty alone did not correct submitral 
problems, therefore, adjunct procedures should be used to address the LV remodeling, prevent 
recurrent FIMR and insure durability of the balanced mitral complex mechanisms after surgery.     
In addition to septo-lateral mitral annular reduction, the PPM repositioning was done by 
using the epicardial apparatus to baso-medially relocate the PPM base toward the mitral fibrosa. 
The concept of this technique was to reduce the tethering distance of the PPM from the mitral 
annulus and the interpapillary muscle distance. In conclusion, this study demonstrates the 
feasibility of an epicardial correction to study geometric changes after mitral annular reduction 
alone compared to PPM repositioning adjunct with mitral annulus reduction in a pulsatile ex vivo 
heart model of FMR. This study was aimed to fulfill the gap of the complex FIMR mechanisms 
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Functional ischemic mitral regurgitation is associated with complications and poor 
prognosis after cardiac surgery. The risk of heart failure and mortality significantly worsen with 
increased MR severity. Regarding to normal mitral leaflet structures, FIMR is related to 
dilatation of the mitral annulus and restriction of the mitral leaflets mobility during systole due to 
papillary muscles (PMs) displacement. FIMR patients have restricted leaflet closure from the 
tethering force influenced by the apically displaced PMs and concurrent dilated annulus. 
Mitral valve repair has been a favorable option for many decades. Mitral annular 
dilatation has been hypothesized as the main predictor for FIMR, therefore, reduction mitral ring 
annuloplasty has been used as the treatment of choice for FIMR. However, significant recurrent 
MR as high as 20-30 percent could be found post-annuloplasty and the outcomes varied among 
patients. Ring annuloplasty alone incompletely addresses the subvalvular components 
contributing to MR. Recently, clinical researches have been focusing on patients with moderate 
to severe FIMR requiring an adequate surgical strategy addressing the subvalvular apparatus to 
improve the long-term durability of the repair and prevent reoperation from recurrent MR.  
Experimental and clinical studies increased interest in surgical techniques targeting the 
subvalvular area. More studies and technical development are needed, since there is no best 
treatment at present.  
There have been few heart models developed to test mitral valve function in an ex vivo 
state due to the technical difficulties. Developing a pulsatile heart model mimicking clinical 
findings in FIMR patients could be a favorable option for usage in the primary stages of the 
study. Therefore, the first goal of this dissertation was to develop an ex vivo pulsatile heart model 
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to help facilitate FIMR studies and use for further studies on FIMR mechanisms and designing 
optimal treatment strategies. Our second goal of the study was to utilize the pulsatile ex vivo 
heart model to evaluate geometric changes of the mitral apparatus in PPM displacement despite 
normal annular size. We would like to study the parameters that have not been reported including 
the tethered angle of the PMs referred to the annulus.  
Reduction annuloplasty with adjunct procedures were combined to address the remodeled 
LV and prevent recurrence of FIMR after annuloplasty. Subvalvular surgical techniques that 
focused on correcting the PMs displacement by repositioning the PPM affect both mitral leaflets, 
since both leaflets were suspended by PMs. Studies have shown cut-offs and predictive values 
for tethered angles and distances of the mitral leaflet but few have focused directly on the PMs 
itself. This study can help us know how to manipulate the PPM to achieve balanced leaflet 
closure which could we assessed by MR reduction. The final goal was to demonstrate how 
additional subvalvular repositioning of the PPM by adjusting the epicardial surface could affect 
MR volume and other geometric parameters. Many subvalvular techniques required extended 
aortic clamping and cardiopulmonary bypass (CPB) time which is not ideal to lower post-
operative complications. Developing additional subvalvular techniques that required less or does 
not require CPB time is more favorable. The knowledge that we gained from this research study 
should provide more depth in FIMR mechanism, moreover; it showed the preliminary data on 










Mitral regurgitation is a retrograde flow from the left ventricle into the left atrium during 
systolic phase when normal mitral valve tends to close. The causes can be from an ischemic and 
non-ischemic event. MR is usually classified into 3 types by the functional characteristics of the 
leaflets;18  
 
Type I – normal leaflet motion with mitral annular dilatation and/or leaflet perforation  
Type II – excessive leaflet motion; such as papillary muscle rupture 
Type III – restricted leaflet movement  
Type IIIa- restriction during diastole; such as rheumatic disease 
Type IIIb- restriction during systole; such as functional disease and cardiomyopathy 
 
In this dissertation, we will focus on secondary ischemic MR, or aka functional ischemic 
mitral regurgitation, which is one of the major cause of MR in western countries and the standard 
treatment strategies are still uncertain.23 Ischemic heart disease is the leading cause of 
cardiovascular (CVS) deaths in the United States and worldwide.15 Approximately 1 million 
people in the United States are diagnosed with ischemic heart disease annually.15 Within this 
numbers, 20-30 %,10,11,17,61,64 or as high as 59% will encounter FIMR.36 FIMR occurs despite 
structurally normal mitral leaflets and is characterized by most commonly type IIIb and 
occasionally Carpentier type I functional classification. It is a common complication found after 
myocardial ischemia and is often overlooked in coronary artery disease patients.79 FIMR is 
associated with complications and poor prognosis after cardiac surgery.7,57 Even with mild MR, 
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the risk of heart failure and mortality significantly increases. Outcomes are worse with increased 
severity of FIMR.11,30,31,60,70  
 
 
2.1 Mitral apparatus  
 We have to understand the anatomy of the mitral apparatus to better understand the 
mechanisms and apply on how to efficiently treat FIMR. The mitral apparatus consisted of 6 
components including the left atrial wall, mitral annulus, mitral leaflets, chordae tendineae, PMs 
and the LV wall.89 The balanced function of the mitral apparatus ensures normal leaflets closure. 
 
2.1.1. Left atrial wall 
 The left atrial wall has continuity with the mitral annulus and mitral leaflets. Therefore, 
enlargement of the left atrium can contribute to MR by directly displacing the posterior mitral 
leaflet. The anterior mitral leaflet is not mainly affected since its base is connected to a more 
stationary structure (atrioventricular septal area).65 Although the left atrial wall contraction and 
relaxation seems to associate with mitral leaflets coaptation. Human study has shown that MR 
was not noticeable in the absence of left atrial contraction.111  
 
2.1.2. Mitral annulus 
 The mitral annulus is mainly collagenous tissue that separates the left atrium and the left 
ventricle. It is the basal attachment of the mitral leaflets. The mitral annular area reduces 25-50% 
and has a saddle shape during systole both in human and in animal models.3,46,50,97 The annular 
size and saddle shape are associated with complete leaflet coaptation.37  
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2.1.3. Mitral leaflets and chordae tendineae 
 There are 2 main mitral leaflets, the anterior (septal) and posterior (lateral) mitral leaflets. 
The anterior mitral leaflet (AML) has a semicircular shape with no scallop and spans between 
the commissures of the mitral annulus in the fibrous trigone region. The base of the AML is 
connected with the aortic annulus. The posterior mitral leaflet (PML) consisted of 3 scallops and 
spans 2/3 of the lateral annular circumference in adjunct with the atrioventricular groove (Figure 
2.1). These individual scallops are believed to help leaflet opening during diastole. The height of 
the normal PML is less than half of the AML; however, each mitral leaflet takes up 50% of the 
mitral orifice area during leaflet closure. The rough zone or coaptation zone is the free margin 
area at the atrial side of the leaflets. This represents the coaptation surface of the valve. The non-
coaptation surfaces of the leaflets are called the smooth zone. 
 
Figure 2.1. Mitral leaflets nomenclature. AML, Anterior mitral leaflet; PML, posterior mitral 
leaflet. The PML has 3 scallops, P1-P3. The AML is divided into three coaptation segments (A1-
A3) that oppose the PML scallops. 
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The chordae tendineae connect mitral leaflets to the PMs and LV wall. They act as the 
leaflet suspension system which maintain the position and tension on the leaflet throughout the 
cardiac cycle. They are divided into 3 groups depending on the attachment sites of the mitral 
leaflets.  The marginal or “primary” chordae attach to the free margin of the leaflets. They 
prevent prolapse of the leaflet when the left ventricular pressure (LVP) increases during systole. 
Strut or “secondary” chordae attach to the ventricular surface of the leaflets rough zone and 
smooth zone. They contribute to ventricular-valve continuity and optimize systolic function. The 
strut chordae that attach the PML are called “intermediate” chordae. Basal or “tertiary” chordae 
connect the PML at the base near mitral annulus to the LV wall.  
 
2.1.4. Papillary muscles and left ventricular wall 
The PMs and the LV wall are the muscular portions of the mitral apparatus. There are 
two PMs; the anterior papillary muscle (APM) and the posterior papillary muscle (PPM). Each 
papillary muscle has chordae tendineae connecting both AML and PML. A geometric study in 
ovine hearts revealed that the interpapillary muscle tip distance was 2.1 cm and the distance 
between the PPM tip and the annular fibrosa was 2.6-2.8 cm.51  
The LV is supplied by 3 major arteries; left anterior descending artery, right coronary 
artery and left circumflex artery. LV remodeling after myocardial infarction in human commonly 
associated with asymmetrical LV remodeling of the inferior wall (PPM region) of the heart since 
63% of the cases are mainly perfused by a single blood supply from either the posterior 
descending branch of a dominant right coronary artery or by the third obtuse marginal branch. 
On the contrary, 71% of the cases have dual blood supplying the APM, the first obtuse marginal, 
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originating from the left circumflex artery, and the first diagonal branch, originating from the left 
anterior descending, which makes it less vulnerable to infarction and rupture.113   
Each mitral component plays an important part for mitral leaflet competence. The 
synchrony of the mitral apparatus working as a whole unit prevents MR during isovolumetric 
contraction and ejection phase in the cardiac cycle. Disruption of this synchronized function or 
abnormality of mitral apparatus after myocardial ischemia can result in FIMR. 
 
 
2.2. Mechanisms of FIMR 
Mitral valve competence consisted of complex mechanisms contributing to the process of 
systolic leaflet cooptation. Therefore, any alterations in one or more of mitral structures could 
contribute to regurgitation. Regarding to normally mitral leaflet structures, patients that 
developed MR after myocardial infarction had more dilated annulus compared to normal 
patients.39,57,103 Tibayan and colleagues103 used chronic ovine FIMR models to demonstrate that  
FIMR was associated with greater septo-lateral annular dilatation compared to non-FIMR 
animals. Asymmetrical annular dilatation usually occurs at the lateral annulus, which is bordered 
with the free wall of the LV. Where else the septal portion, which is adjacent to the 
interventricular septal area, obtained lesser geometric changes.59 This event is secondary from 
LV dilatation and remodeling after cardiac ischemic events. In FIMR patients, the mitral annulus 
dilates, looses its saddle shape and becomes more flatten as asymmetrical septo-lateral dilatation 
progresses.37,53,63,97 The mitral annular dynamic contraction is also reduced.63,97  
Although annular dilatation is a common finding in FIMR and mitral annular area was a 
strong predictor of MR,101 it is uncertain whether it is the major determinant of FIMR or not, 
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since annular dilatation alone did not produce significant MR.88 Moreover, persistent and 
recurrent FIMR could be found after reduction mitral annuloplasty.43,57,71 This shifts the 
knowledge of FIMR to a more ventricular problem. The current knowledge of FIMR 
mechanisms is shown in Figure 2.2. Historically, PMs function was suggested as a determinant 
of FIMR, a study in FIMR patients showed that PMs longitudinal systolic strain did not affect 
MR severity.105 Left ventricular remodeling occurs typically after posterior-lateral (inferior) 
myocardial infarction.57 This mainly causes asymmetrical PMs displacement at the level of the 
LV wall where ischemia occurs.48,82  In a ovine model of FIMR, the PPM was displaced 
laterally, apically and posteriorly.103 The interpapillary muscles distance increased significantly 
in FIMR patients55 and was the only independent predictor for FIMR severity.48 Uemura and 
colleagues have showed that increased PPM tethering distance from the annular fibrosa was the 
only independent risk factor MR severity in FIMR patients.105 Papillary muscles displacement 
after LV remodeling induced systolic tenting of mitral leaflets away from the annulus causing 
incomplete leaflets closure.  
FIMR patients have restricted leaflet closure due to tethering force influenced by the 
displaced PMs and concurrent dilated annulus. Echocardiography is an essential tool used to 
investigate leaflet configurations. Preoperative tethering angles of both AML and PML were 
major determinants for FIMR.114 The tethering angle is measured as the angle between the mitral 
annulus and the AML or PML. Tenting area, coaptation depth, annular dilatation, and left atrial 
size were all associated with baseline MR severity. Many studies have found that leaflet 
tethering angles, AML bending angle and coaptation heights were related to recurrent MR after 







Figure 2.2. This schematic features the mechanisms of FIMR. After myocardial infarction, (1) 
the LV remodeled along with (2) mitral annular septo-lateral dilatation occurred. (3) The PPM 
displaced apically and laterally pulling the (4, 5) leaflets down toward the LV apex which 









Table 2.1. Predictive parameters for recurrent FIMR after ring annuloplasty. 
Authors Pre-operative predictor 
Calafiore et al.,  2014 13 Coaptation depth >10mm, 
AML bending angle >145°  
Magne et al., 2007 69  PML tethering angle ≥ 45 degrees 
Troubil et al., 2012 104 AML tethering angle ≥27 degrees 
van Garsse et al., 2012 112 Anterior/posterior tethering angle ratio >0.76 
Gelsomino et al., 2008 33  LVESV ≥145mL 
LV systolic sphericity index ≥0.7 
LV myocardial performance index <0.9 
LV wall motion score index <1.5 
Roshanali et al., 2007 95 Interpapillary muscle distance of 20mm  
(base to base measurement at end systole) 
Bouma et al., 2016 9 P3 tethering angle  >29.9 degrees 
Kuwahara et al., 2006 58  PML tethering angle 
Gelsomino et al., 2008 33 
van Garsse et al., 2012 112  
AML tethering angle ≥39.5 degrees  
 
Modified from Jensen et al. 2015. Surgical treatment of functional ischemic mitral regurgitation. 
Dan Med J 65(3): B4993.47  
 
 
2.3. Surgical treatments  
Surgical treatments were aimed to eliminate MR and restore LV function. Coronary 
artery bypass grafting (CABG) was used to treat ischemic myocardiopathy and mitral valve 
surgery was added to treat the dilated annulus. Mitral valve repair had more benefits than mitral 
valve replacement in moderate FIMR.35 Mitral valve repair at the time of CABG significantly 
reduced MR grade and increased LV ejection fraction.27 A sub-analysis of the STICH (Surgical 
Treatment for Ischemic Heart Failure) trial supported that adding mitral annuloplasty to CABG 
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improved moderate to severe MR and survival rate compared with CABG alone or medical 
therapy alone.23  
 
2.3.1. Ring annuloplasty 
In addition to CABG, mitral valve repair by ring annuloplasty were used as FIMR 
treatment for many decades.8,40,110 Lillehei and colleagues first introduced the concept of 
annuloplasty for mitral insufficiency correction in 1957.67 In 1961, the annuloplasty ring was 
first invented and used by Carpentier.18 Today, there are many types and sizes of mitral 
annuloplasty rings used for FIMR treatment.50,71,99 Reduction annuloplasty gain popularity after 
Bolling and Bach reported the efficacy of using reduction annuloplasty for MR patients.6 
Reduction (or restricted or undersizing) mitral annuloplasty was done by using an annuloplasty 
ring 1–2 sizes smaller than the normal ring size based on the AML height and annular 
intertrigonal distance. This procedure had high successful rate in short-term studies22,87 and is the 
current treatment of choice for FIMR.87 To minimized cardiopulmonary bypass (CPB) time and 
complication, the transcatheter mitral annular techniques were developed.60,90,100 Although this 
idea reduced high-risk complications, most techniques had limitations such as limited septo-
lateral annular dimensional reduction from the anatomical position of the coronary sinus, 
dislodging, unequal tension on the left atrium and mitral annulus.20 
Surgical leaders have used reduction annuloplasty techniques to treat FIMR patients for 
many decades. This approach solely addressed the annular dilatation; however, it did not address 
the LV remodeling, PMs displacement and leaflet tethering. Despite early satisfactory outcomes 
of mitral annuloplasty, late recurrence of FIMR has been observed in a significant number of 
cases.12,35,47,71 Approximately 10-20 percent of the patients after 5 years of ring annuloplasty had 
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recurrent FIMR and progression of LV remodeling.31 Jensen and colleagues has summarized 35 
studies published between 2001-2012 on adding ring annuloplasty to CABG in patients with 
moderate to severe FIMR. This study revealed 20-30% post-operative recurrence of FIMR after 
2-4 years follow-up, despite half of the studies have used aggressive reduction ring 
annuloplasty.47 High recurrent rate might be due to restricted leaflet mobility, augmentation of 
the posterior leaflets causing tethering of the leaflets, ongoing LV remodeling, PMs displacement 
outside of the mitral annulus, or combinations of the following events.  
The concept of ring annuloplasty is to bring the annular dimension closer together so that 
the mitral leaflets can completely form coaptation. Although the annuloplasty ring shifts the 
lateral annulus closer to the septal annulus, reduction annuloplasty alone could worsen PML 
restriction by increasing the distance between the already lateral displaced PPM and the lateral 
portion of the annulus (Figure 2.3.A).39,43,58,114 Green and colleagues39 reported that restricted 
PML was associated with persistent and early post-annuloplasty recurrent MR. Therefore, ring 
annuloplasty could exacerbate leaflet tethering when the reduction of annular dimension 
exceeded the LV remodeling.43,114  
Continued LV remodeling was presented in patients after reduction annuloplasty and 
could further worsen the imbalanced LV-mitral ring ratio (Figure 2.3.B). Hung and colleague43 
have reported that recurrent MR after ring annuloplasty was associated with continued LV 
remodeling. Capoulade and colleague16 showed that the LV-mitral ring mismatch ratio after 1 
year post-operative ring annuloplasty was significantly associated with recurrent moderate or 
greater MR in the Cardiothoracic Surgical Trials Network (CTSN) randomized trials.  
Reduction annuloplasty did not address the LV complex mechanism of FIMR. Therefore 
adjunct procedures were needed to address the PMs displacements from the remodeled LV, 
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relieve the tethered leaflets and prevent recurrent FIMR after annuloplasty. Many studies have 
looked at subvalvular treatments to help correct the LV problem. Annuloplasty combined with 
adjunct subvalvular techniques (e.g. chordal cutting, direct papillary muscle relocation and PMs 













Figure 2.3.  Schematics of (A) persistent and (B) recurrent MR after ring annuloplasty.  
 
 
2.3.2. Chordal cutting 
In 2001, Messas and colleagues74 developed chordal cutting by severing 2 strut chordae 
which restricted the AML in a rigid open position bend in the basal anterior leaflet (“seagull 
sign”). Chordal cutting did not impair LV function.73-75 It increased AML mobility without 
A.      B. 
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leaflet prolapse in animal studies. Eventually, polytetrafluoroethylene chordal suspension sutures 
could be done if leaflet prolapse occurs. This procedure relied on the AML to act as a unileaflet 
since the PML remained vertically rigid due to relatively lateral PPM displacement from 
reduction annuloplasty. Therefore, the AML needs to have adequate tissue length to maintain 
complete closure. The indication for strut chordal cutting is when the AML bending angle is 
<145° and the coaptation depth ≤10mm.14,34  
Szymanski and colleagues compared isolated reduction annuloplasty versus isolated 
bileaflet chordal cutting versus the combined therapy in ovine models with mild to moderate 
FIMR. After surgical treatments, MR in the combined treatment group was reduced to trace and 
the LV end-systolic volume in the combined treatment was significantly lesser than each 
intervention alone (P<0.01).101  
 
2.3.3. Papillary muscle relocation (Kron’s technique) 
In 2002, Kron and colleagues56 were the first to clinically use PMs relocation by using 
suture material to anchor the PPM tip to the lateral annulus. The concept of this procedure was to 
lower the distance between the PMs and the mitral annulus which believed to reduced leaflet 
tethering. The original technique used pledgetted suture to anchor the PPM tip toward the mitral 
annulus near the posterior fibrous trigone prior to reduction annuloplasty in chronic FIMR 
patients. In this study, no patients had recurrent MR 2 months postoperatively. This technique 
could be easily reproduced and decreased early and late mortality.56 PPM relocation alone 
reduced MR in ovine models of acute FIMR. (Langer 2005) Modification of this technique was 
done by adding APM relocation to the original technique in a porcine experimental model. 
Results showed reduced PPM-anterior annular distance and lateral leaflet tethering compared to 
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isolated reduction annuloplasty.49 Recently, Fattouch and colleagues28 reported a midterm 
follow-up that PPM relocation adjunct to non-reduction ring annuloplasty decreased recurrent 
MR and improved reversal in LV remodeling than isolated reduction ring annuloplasty in 
patients.28,29 In addition to ring annuloplasty, Langer and colleagues58 modified the Kron’s 
technique to allow adjustment of the PPM relocation under partially loaded beating heart. This 
technique is called the ‘RING+STRING’. They have reported less MR residual when applying 
this technique in moderate to severe FIMR patients undergoing CABG and reduction 
annuloplasty.62  
 
2.3.4. Papillary muscle approximation 
Papillary muscles relocation or the RING+STRING techniques correct tethering at the 
subvalvular level. However, relocating the PMs could not reduce apical, posterior and outward 
tethering since the PMs were suspended toward the mitral annulus. Therefore, these procedures 
were not ideal for patients with severe LV remodeling when the PMs were displaced far apart. 
Papillary muscle approximation is a procedure that was developed to correct mitral leaflets 
tethering, especially in the outward and posterior directions, by directly reducing the displaced 
PMs. The concept of PMs approximation was to correct tethering by decreasing the 
interpapillary muscles distance due to LV remodeling. The PMs could completely be 
approximated (complete PMs approximation) through an LV incision or partially at the level of 
the PMs tips to the mid portion (incomplete PMs approximation) through the mitral or aortic 
orifice.92  
Papillary muscle approximation in combination with reduction annuloplasty reduced 
recurrent MR and improved reversal of LV remodeling when compared to reduction 
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annuloplasty alone in a randomized clinical trial (Papillary Muscle Approximation trial) of 
severe FIMR patients.86 Similarly, results from a 5-year randomized controlled clinical trial 
comparing patients who either had PMs approximation in combination with reduction 
annuloplasty or reduction annuloplasty alone showed that the mortality rate after 2-year follow-
up was significantly higher in the isolated reduction annuloplasty group. The combined treatment 
had better LV reverse remodeling at 5-year follow-up. At the last follow-up, patients with 
reduction annuloplasty had 55.9% moderate or severe regurgitation compared to 27% in the 
combined group.84,85 Wakasa and colleagues107 compared outcomes between complete and 
incomplete PMs approximation. They found that the complete group was associated with lower 
mortality and a lower moderate or greater recurrent MR. The 4-year survival rate and rate of 
freedom from moderate or greater recurrent MR were 83% and 85% for those with complete 
PMs approximation, respectively.107  
These subvalvular techniques directly helped correct PMs displacement and reduced the 
tethering force on the leaflets. Nevertheless, the combination of CABG procedure, mitral repair 
and additional subvalvular techniques required additional aortic cross-clamping and surgical 
assisted-CPB time or placement of synthetic sutures or prostheses inside the LV 
chamber.26,42,44,56 CPB for cardiac surgery is related to morbidity and mortality.83 Multivariate 
analyses done by Salis and colleague have revealed that 30-minute increment of CPB time is an 
independent risk factor for postoperative death.98 The common postoperative complications in 
cardiac surgery assisted with CPB are systemic inflammation responses, acute renal injury and 
pulmonary complications.66,81,102 Seven percent of the patients undergoing assisted-CPB cardiac 
surgery will develop postoperative acute renal injury, where else pulmonary complications in 
cardiac valvular surgery range from 5-7 percent and 3-16 percent in CABG.96,98,109 This 
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influenced researchers to focus on interventions that do not require CPB by using extra-mural 
devices placed over or insert through the epicardium. In 1999, Power and colleague88 have 
proven that a passive LV constraint mesh placed around both ventricles known as “Acorn 
device” can lower functional MR by indirectly decreasing PMs displacement.1,2,91 Coapsys, a 
trans-ventricular device that reduces LV dilatation between the PMs, has shown promising 
results compared to ring annuloplasty, but further studies were terminated from discontinued of 
funding.19,45 Newer studies of epicardial devices are being tested and validated such as the 
“Basal Annuloplasty of the Cardia Externally (BACE) device”, which is a silicone band placed 
apically to the atrioventricular groove.93 This device is mainly for treatment of annular dilatation 
with or without PMs displacement in FIMR patients. It can be inflated to modify the ventricular 
component and correct MR.93  
As mentioned earlier, mitral valve surgery gave suboptimal results and late recurrent MR 
was found in significant number of cases. Patients that did not required CABG would rarely 
receive mitral valve surgery. Therefore, minimally invasive transcatheter mitral valve repair 
strategies were used as an alternative MR treatment. These strategies were developed to mimic 
standard surgical approaches including annuloplasty, edge-to-edge repair, chordal plication and 
LV remodeling.20 At present, the MitraClip system is Food and Drug Administration (FDA) 
approved for primary MR and used widely compared to other transcatheter mitral valve repair. 
There are ongoing treatment studies for FIMR.5 MitraClip used the same concept as the edge-to-
edge repair, based on the surgical Alfieri technique,4 by grasping and clipping a free margin of 
the AML and PML together. The prospective multicenter single-arm study to evaluate the 
feasibility, safety, and efficacy of the MitraClip system (EVEREST I) showed that freedom from 
death and freedom from surgery were 94% and 76.3% after 3 years, respectively.32  
 18 
All techniques as mentioned above, have their own advantages and disadvantages and no 
studies have definite comparison of these procedures. As mentioned earlier, the complete 
mechanisms of FIMR is unclear which makes it harder to develop a surgical treatment of choice. 
More studies in this area are needed to optimize and improve new strategies for FIMR treatment.  
Developing new surgical tools and techniques for FMR treatment requires excessive testing and 
validation. Animal trials are normally used for standard testing but requires time and expenses. 
Utilizing ex vivo heart models could be a favorable option in the primary stages of the testing and 
validating new surgical strategies, since it is more cost efficient, required less time, reduced 
complexity, lessened the need of laboratory animal usage and sacrifice. In 1997, He and 
colleagues41 developed an in vitro model of FMR. The model was used for studying the 
independent variation of PMs position, annular size, and trans-mitral pressure. The mitral valve 
and the attached PMs were dissected and fixed to an annulus board mounted in a pressurized 
chamber. Many studies have adopted this idea and used it for studying FMR, chordal rupture and 
other mitral apparatus abnormalities.25,52 The downside was that it did not have physiological 
mitral opening and continuity LV as in intact heart. An in situ heart model was developed by 
isolating and maintaining the beating heart for several hours.21 This model was ideal for ex vivo 
studies, since it mimics physiological cardiac function. However, it required complex preparation 
and did not eliminate the use of additional laboratory animals as recipients for heart 
transplantation. In 2009, an intact heart model with pulsatile pressurization was developed by 
Richard and colleagues.94 They aimed to facilitate surgical correction of annular dilation and 
chordal rupture. In 2013, Monnet and colleague published a study of an ex vivo heart model of 
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The hypotheses of this dissertation are as follow: 
Hypothesis 1: It is assumed that MR can be induced in an ex vivo pulsatile heart model by 
sufficient displacement of the PPM despite normal mitral annulus. Determination of the 
effectiveness of the heart model and quantifying the MR severity were conducted by measuring 
MR flow and the geometry of the mitral apparatus when different degrees of PPM displacement 
was applied to the ex vivo heart model. The aims to accomplish the hypothesis are as follow: 
Aim 1.1:  To examine the chances of producing MR flow in heart models with different 
degrees of PPM displacement. 
Aim 1.2:  To examine the geometric changes of the PPM compared to baseline in 
different degrees of PPM displacement by using sonomicrometric measurements. 
 
Hypothesis 2: We hypothesized that the tethered distances and tethered angles of the PPM 
increases from baseline in the ex vivo heart models that developed MR compared to heart models 
that did not developed MR. Evaluation of the geometric tethered distances and tethered angles of 
the PPM compared to baseline should give additional information on the mechanisms of FMR 
despite normal mitral annulus. The aims to accomplish the hypothesis are as follow: 
Aim 2.1: The 3D tethered distances and tethered angles of the PPM after inducing left 
ventricular dilatation and PPM displacement were compared to baseline. 
Aim 2.2: To identify the geometric determinants that were associated with MR volume 
despite normal mitral annulus. 
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Hypothesis 3: Additional subvalvular PPM repositioning by using epicardial apparatus lowers 
MR compared to isolated septo-lateral annular reduction. The aims to accomplish the hypothesis 
are as follow:  
Aim 3.1: We assessed the results of isolated septo-lateral annular reduction and 
additional PPM repositioning. The ex vivo pulsatile heart model was used to determine 
the physical changes of the annulus and PMs before and after epicardial contouring 
apparatus. Reducing the septo-lateral mitral annular dimension adjunct with reversing the 
PMs displacement in the baso-septal position can reduce greater MR.  
Aim 3.2: Piezo-electric crystals were used for tethered distance measurements and the 
three dimensional (3D) geometry of the mitral apparatus. Differences of the mitral 
annular area (MAA), annular septo-lateral dimension and geometry of the PMs tips from 
the heart model were assumed to have an effect on the MR volume through different 
degrees of the LV epicardial apparatus adjustments. We aimed to show how septo-lateral 
mitral annular reduction, overall papillary muscle tethering distances, 3D PPM geometry, 










4. LEFT VENTRICULAR DILATATION AND POSTERIOR PAPILLARY MUSCLE 





Functional mitral regurgitation is defined as regurgitation due to dysfunction of the mitral 
apparatus with normally structural mitral leaflets causing incomplete closure of the mitral orifice. 
Remodeling of the LV wall after cardiac ischemic event altered ventricular geometry inducing 
papillary muscles displacement.12 Displacement of the papillary muscles exerts traction of the 
leaflets through the chordae causing the leaflets to tether and restricting it from normal 
coaptation. Other factors proposed to cause FMR are asymmetrical dilatation of mitral annulus 
and increased LV sphericity.3,11,17,19 
Patient with heart failure carries a worse prognosis in the long term when FMR 
developed.12 Mitral annular dilation and the displacement of the PPM are main components for 
imbalanced forces causing leaflets mal-coaptation. Understanding and assessing the geometry of 
these components and the limitation of standard ischemic FMR repairs can improve and provide 
better treatment strategies.1 One way to determine the mechanism of imbalance forces on the 
leaflets leading to FMR is by using ex vivo heart models. Furthermore, heart models can be use 
in initial studies of surgical strategies for FMR treatments to lessen the cost and time compared 
to animal models and clinical studies.  
Effective ex vivo heart model that mimics FMR have been reported, 10,18,20 but none are 
suitable for studying LV remodeling and PPM displacement. Monnet and colleague15 developed 
an ex vivo model that has the continuity of the LV wall. Annular dilatation, posterior papillary  
 
 32 
muscles repositioning or both were used for induction of LV dilatation and FMR. However, the 
model was built with a static continuous retrograde flow through the aorta. 
The purpose of this study is to develop a pulsatile ex vivo model of FMR with a forward 
flow through the apex of the LV. Determination of the effectiveness of the model and 
quantifying the MR severity were conducted by measuring MR flow and the geometry of the 




4.1 Material and methods 
4.1.1. Heart preparation 
Fresh ovine hearts were collected from 36 adult Dorsett sheep 70±5 kg euthanized for 
reason not related to this study, stored at 4°C. They were prepared for the experiment within 24 
hours of euthanasia. Excessive tissue and the pericardium were trimmed out leaving the aorta 
and pulmonary veins intact. The aorta and LV apex were cannulated with a 3/8” cannula. A 
valve was placed on the cannula coming out of the aorta to control resistance of the output flow. 
The largest pulmonary vein was cannulated with a 1/4” cannula and the rest of the vessels were 
secured with sutures. The cannula that was placed into the pulmonary vein that had an orifice 15 
cm above the mitral annulus. This was used for measurement of MR flow at 15 cm of water 
pressure (11 mmHg). The cannulated aorta and the LV apex were connected to the pulsatile 
pump system (Figure 4.1). The pulsatile pump infused the heart with water at room temperature 
at a rate of 40 cycles per minute with an average flow of 4 L/min. A pressure transducer (Millar, 
Houston, Texas, USA) was inserted through the aorta into the LV to measure the left ventricular 
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pressure (LVP). Maximum LVP for each cycle was maintained above 70 mmHg throughout the 
experiment by adjusting the flow of the pump or resistance in the cannula in the aorta. The 
pulsatile pump generated a pulsatile flow traveling in a forward flow from the LV apex to the 
aorta. 
To allow displacement of the PPM, a full thickness incision was made in the wall of the 
LV around the PPM without damaging the chordae. The PPM remains attached to the apex of the 
LV with a 2 cm strip of myocardium and to the mitral valve leaflets with the chordae. The left 
atrium was incised to expose the mitral annulus and leaflets. Under direct visualization, 2 mm 
piezo-electric crystals (2 mm round Piezo-electric crystals, Sonometrics, London, Canada) were 
carefully tunneled into the endocardium based on prior studies on papillary muscles 
geometry.4,5,15 Six 2 mm piezo-electric crystals (2 mm round Piezo-electric crystals, 
Sonometrics, London, Canada) were placed to determine geometry of the annulus and the 
displacement of the PPM (Figure 4.2). Patches of diaphragm were sutured around the PPM 
muscle and the remaining LV wall to reestablish the integrity of the LV. Patches of different 
sizes were used to induce different degrees of displacement of the PPM. The transducers were 
connected to a data acquisition system (Sonosoft, Sonometrics, London, Canada). 
The hearts were randomly assigned into 3 different sizes of diaphragmatic patches: Small 
patch (SP) group, Medium patch (MP) group, and Large patch (LP) group. The patch was 1, 2 
and 3 cm at the widest point for the SP, MP, and LP group respectively (Figure 4.3). It was 
sutured with 4-0 suture materials with continuous suture pattern as described by Monnet et al.15 
Distances between each pair of transducers were measured at maximum LVP of each cycle at 
baseline and after placement of the patch. The MR flow was measured in milliliter per minute 
(ml/min). Displacement of the PPM and mitral annular geometry were evaluated at maximum 
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LVP. Heart with maximum LVP lesser than 70 mmHg, abnormalities of the mitral apparatus 
such as rupture and tear, severe leakage after patch placement and dislocation of the piezo-
electric crystals transducers were excluded from the study. 
 
4.1.2. Statistical analysis 
 Data from MR flow and dimension between transducer pairs were expressed as median 
and interquartile range (IQR) at maximum LVP of the cardiac cycle both at baseline and after 
patch placement. Comparison of the paired continuous variables in each treatment group from its 
baseline was performed by Wilcoxon Signed-rank test. A Kruskal-Wallis Test was used for 
comparing continuous variables between treatment groups and comparison of unpaired 
continuous variables was done by Wilcoxon rank sum test. Categorical variables comparison was 






















Figure 4.1. Dynamic pressurization system that generates pulsatile forward flow (indicate as 
black arrows) through the left ventricle. Mitral regurgitation flow was collected at 15 cm above 






Figure 4.2. Location of the piezo-electric crystals placement. Piezo-electric crystal #1 was 
placed at the level of the septo-lateral (fibrosa) part of the mitral annulus and piezo-electric 
crystal #2 was placed opposite side of piezo-electric crystal #1 on the mid-lateral part of mitral 
annulus. Piezo-electric crystal #3 was placed at the anterior commissure of the mitral annulus 
and piezo-electric crystal #4 at the apex. Piezo-electric crystals #5 and #6 were placed on the tip 




Figure 4.3. Illustrates the (A) “U”-shaped incision made around the PPM, (B) three sizes of crescent-shaped diaphragmatic patches 
and (C) after application of the diaphragmatic patch; Ao, Aorta; Au; Right auricle; Dp, diaphragmatic patch; LV, Left ventricle. 
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Thirty-six hearts were used in the study. After placement of the diaphragmatic patches, 
22 hearts were included in the final analysis of this study. Fourteen hearts were excluded from 
the study due to failure to maintain LVP from leakage at suture line (10 hearts), dislodging of the 
ultrasound transducer (1 heart) and torn left atrium (3 hearts). Seven hearts were in the SP and 
MP groups and eight in the LP group. Eleven hearts produced mitral regurgitation: 2 in each of 
the SP and MP group; 7 in the LP group.  
Left ventricular pressure measured at baseline and after patch placement are reported in 
Table 4.1. At baseline and after patch placement, maximum and minimum pressure were not 
significantly different when compared between the 3 treatment groups (P>0.05). After patch 
placement, maximum and minimum pressure were not significantly different compared 
respectively to baseline (P>0.05). The maximum LVP for each treatment group was significantly 
higher than the minimum LVP (P=0.0156, 0.0156 and 0.0078 for SP, MP and LP groups 
respectively). The pressure-time relationships before and after applying the patch generated by 
the pulsatile pressurization system are illustrated in Figure 4.4. 
 Measured MR flow was reported in Table 4.2. Mitral regurgitation flow increased 
significantly after applying the large patch from 0 ml/min at baseline to 554 ml/min (IQR: 185-
1,919.3 ml/min, P=0.0156). There were no significant changes in the MR flow from baseline in 
the SP and MP groups (P>0.05). In the LP group, 87.5% of the heart had mitral regurgitation 
while 28.6% of the heart in the SP and MP groups developed mitral regurgitation (P=0.034). 
There was no significant difference between the number of hearts that developed mitral 
regurgitation between the SP and MP groups (P>0.05). Boxplot representing the median and 
interquartile range of MR flow by patch sizes are shown in Figure 4.5. The measured MR flow 
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increased significantly after applying the large patch from 0 ml/min at baseline to 554 (185-
1,919.3) ml/min (P=0.0156). However, there were no significant changes in the MR flow from 
baseline in both small and medium patch groups (P>0.05). Large patch placement produced 3.06 
times higher MR heart models than the small and medium patches. 87.5% of the large patch 
heart models have MR. The small and medium patch group each produced 28.6% heart models 
with MR. Applying a Fisher’s exact test, the proportion of heart models that produce MR flow is 
significantly higher in the large diaphragmatic patch compared to small and medium patches 
(P=0.034 and P=0.034, respectively). Significant differences in the proportion of having MR 




Table 4.1. Left ventricular pressure after patch placement versus baseline in heart models at 
maximum and minimum pressure. Data is presented as median (IQR). 
Minimum and maximum values similar superscripts were not significant difference (P-value > 0.05). 
 
Patch size Minimum Pressure (mmHg) Maximum Pressure (mmHg) 


































Figure 4.4. Left ventricular Pressure-Time graph during one cycle at baseline and after patch 





Table 4.2. Mitral regurgitation flow by patch sizes. Values are shown as median (IQR) 
Patch size 
Mitral Regurgitation Flow Rate 
(ml/min) 
Number of Hearts with regurgitation 


























Figure 4.5. Boxplot comparison of median mitral regurgitation flow by patch sizes; * Indicates 
significant difference from baseline (P<0.05) 
 
 
Geometric measurements of the mitral annulus and LV at maximum LVP in the three 
groups are reported in Table 4.3. The commissure to commissure annular dimension and mitral 
annular area were not significantly different after patch placement when compared to baseline in 
the three groups. In the SP group, after placement of the patch, the distance from fibrosa to PPM 
(P=0.016) and interpapillary length (P=0.016) increased significantly from baseline. In the MP 
group, after placement of the patch, the distance from the fibrosa to PPM (P=0.031), distance 
from mid-lateral annular to PPM (P=0.031) and interpapillary length (P=0.031) increased 
significantly from baseline. In the LP group, after placement of the patch, interpapillary length 
was significantly increased from baseline (P=0.008). Differences of all the dimensions between 
the three patch sizes were not significant (P>0.05). In the LP group, volume of the LV 
significantly increased from 18.5 ml (IQR: 15.0-26.0 ml) at baseline to 27.5 ml (IQR: 19.5-42.5 
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ml) after applying the large patch (P=0.031). The LVV did not increase significantly from 
baseline in the SP and MP groups (P>0.05).  
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Table 4.3. Geometric measurements of the annulus and lv chamber after patch placement versus baseline in heart models at maximum 
pressure. Values are shown as median (IQR) 
 
SL: Septo-lateral; CC: Commissure to commissure; LVV: Left Ventricular volume; PPM: Posterior papillary muscle; LA: Lateral annular;  
* Denotes P-value <0.05 versus Baseline. 
 Small Patch Medium Patch Large Patch 
Baseline 
(n = 7) 
Patch 
(n = 7) 
Baseline 
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Patch 
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4.3. Discussions  
Application of a patch around the PPM induced LV dilatation and outward displacement 
of the PPM.  Mitral regurgitation resulted from displacement of the PPM without mitral annular 
dilatation. This ex vivo model is using a pulsatile forward flow from the apex of the LV toward 
the aorta.  
Left ventricular pressure was maintained during the experiment. Monnet et al.15 used a 
large patch sutured around the PPM to induce FMR in a static model of LV remodeling. In this 
study after suturing a patch around the PPM a pulsatile flow was used to generate a pressure 
wave in the LV.  The pressure wave was similar before and after placing the patch. A maximum 
LVP of 100 mm Hg was used. The minimum and maximum pressures generated in the LV were 
not affected by the size of the patch sutured around the PPM. The flow was also maintained in a 
forward direction from the apex of the LV toward the aorta, which is more physiologic than the 
direction of the flow used in another study with a continuous flow.15 
Myocardial infarction is commonly associated with asymmetrical LV remodeling with 
outward displacement of the PPM.21 The distance between the fibrosa and the PPM increased as 
well as distance between the papillary muscles. Therefore, this model reproduces the outward 
displacement of the PPM reported in several clinical studies.6,21,22 This was achieved by suturing 
a patch only around the PPM. The outward displacement does not seem to correlate with the size 
of the patch since the distances measured in this experiment were not significantly different 
between the three different sizes of patches. Left ventricular dilatation was only significant with 
the large patch. In clinical cases the dilation is the result of an aneurysmal dilation of the 
infarcted wall around the PPM.6 Only the larger patch resulted in significant MR and LV 
dilatation. In clinical cases, FMR patients had more dilated annulus and LV compared to normal 
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patients.3,12,13 Stretching of the mitral valve annulus is possible.15,18 Annular dilation was not 
induced in this experiment because we wanted to reproduce a model reproducing only tethering 
of the papillary muscle. We wanted a model that would reproduce the LV dilation that is 
occurring after undersized annuloplasty. 7,14 
Despite claiming reduction annuloplasty as the standard treatment for FIMR, recurrence 
of moderate to severe MR can be found 28% post-operatively.14 Balanced forces on the leaflets 
are being explored especially the PPM displacement and the impeding force from the annulus 
being shifted away from the PPM post-annuloplasty.2,8,9 Also having a model reproducing only 
the outward rotation of the PPM would be more valuable for the evaluation of procedures 
targeting specifically modification of the geometry of the LV for treatment of FMR. 
Mitral valve regurgitation developed mostly with the large patch. The amount of mitral 
regurgitation was significantly larger with the large patch because the geometry of the LV and 
the tethering of the PPM on the mitral valve leaflets were more important than with other patches 
used. The LVV was only significantly affected with the large size patch. The interpapillary 
muscle distance during LVPmax increased after application of patches. In vivo studies on FMR 
have showed similar results.8,9 Animal models and clinical cases have shown that ischemic FMR 
was associated with the displacement of the PPM from the septal annulus5,21 similar 
measurements were found in the small and medium patch sizes. Variation of the patch sizes was 
proposed to affect the severity of MR. Although the PPM displacement distances after patch 
placement were not different between the 3 patch size groups, the large patch group produced the 
highest rate of MR and MR volume. This study suggested that using the large patch application 
for the proposed pulsatile ex vivo model of FMR was more appropriate. Larger patch sizes have 
been used in previous studies and have resulted in larger volume of MR15 with a patch of 5 cm at 
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its widest point. The MR was 1383 ml/min which was higher than the flow recorded in this 





The ex vivo heart used in the pulsatile system were non-vital tissue; therefore the effect of 
contractility during physiologic cardiac cycle could not be evaluated. To minimize further effects 
from non-vital tissue, the experiment must be done within 24 hours after the animals were 
euthanized. Clinical studies from Otsuji and colleagues16 reported that papillary muscles 
dysfunction or annular dilatation alone were not associate with ischemic MR. This implied that 
the pulsatile ex vivo model in this study despite the absence of contraction could be used for 
assessing other factors associated with the MR severity  
In this experiment lot of ex vivo constructs were rejected for several technical reasons. 
However, the ex vivo constructs were mostly rejected at the beginning when we learn how to 
suture the patches on the myocardium. Also, we noticed that each constructs could only be used 
for a limited amount of experiments because the patches started to tear from the myocardium. A 
maximum LVP of 120 mm Hg was used because when the pressure was increased the 
myocardium was tearing even more frequently. This limitation on the pressure limited the 
variation of the LVV during each cycle. 
Interpreting the results need to be carefully taken into consideration since the mitral valve 
in physiological state closes during isovolumetric contraction phase when LVP rises and the LV 
contraction occurs. If mitral leaflet mal-coaptation occurs, MR will be noticeable during early 
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and late phase of isovolumetric contraction. MR was less seen during mid-phase when LVP 
reaches its maximum (counter acting the tethered force on the leaflets).6 In the pulsatile system, 
the pump generated maximum LVP forcing the mitral leaflet to close and the LVV increased 
from fluid pressurization. Leaflets closed at the same pressurization phase as in physiological 
heart except for in vivo the LVV decreased from LV contraction. 
Patch application mimics LV remodeling which occurs in a 3 dimensional fashion. Our 
study, however, only evaluate the PPM displacement in 2 dimensions. This may be the 
explanation for no significant differences of the PPM displacement distances between the patch 
groups. Studies have shown significant 3 dimensional geometric displacements of the PPM and 
tethered angle of the leaflets.8,13,21 Three-dimensional PPM geometry needs to be assessed to 
give a better idea of how the PPM displacement associates MR severity.  
In conclusion, FMR can be induced in a pulsatile ex-vivo model of LV dilatation and 
PPM displacement. Our model generated LVP waveforms and PPM geometry similar to in vivo 
studies without disrupting the mitral leaflets and chordae while the LV wall remained intact. 
Surgical treatments for FMR that involves annuloplasty, LV wall reshaping and PPM 













1. Braun J, Klautz RJM. 2012. Mitral valve surgery in low ejection fraction, severe ischemic 
mitral regurgitation patients: should we repair them all? Curr Opin Cardiol 27:111-–7. 
2. Capoulade R, Zeng X, Overbey JR, et al. 2016. Impact of left ventricular to mitral valve ring 
mismatch on recurrent ischemic mitral regurgitation after ring annuloplasty. Circulation 
134:1247-56. http://circ.ahajournals.org/content/134/17/1247 
3. Enriquez-Sarano M, Akins CW, Vahanian A. 2009. Mitral regurgitation. The Lancet 
373:1382–94. http://www.sciencedirect.com/science/article/pii/S0140673609606929 
4. Green GR, Dagum P, Glasson JR, et al. 1999. Mitral annular dilatation and papillary muscle 
dislocation without mitral regurgitation in sheep. Circulation 100:II95–II102. 
5. Gorman III M, Gorman RC, Jackson BM, et al. 1997. Distortions of the mitral valve in acute 
ischemic mitral regurgitation. Ann Thorac Surg 64:1026–1031. 
http://www.sciencedirect.com/science/article/pii/S0003497597008503 
6. He S, Fontaine AA, Schwammenthal E, Yoganathan AP, Levine RA. 1997. Integrated 
mechanism for functional mitral regurgitation. Circulation 96:1826-1834 
http://circ.ahajournals.org/content/96/6/1826 
7. Hung J, Solis J, Handschumacher MD, et al. 2012. Persistence of mitral regurgitation 
following ring annuloplasty: is the papillary muscle outside or inside the ring? J Heart Valve 
Dis 21(2):218-24.  
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3509931 
8. Jensen H, Jensen MO, Smerup MH, et al. 2010. Three-dimensional assessment of papillary 
muscle displacement in a porcine model of ischemic mitral regurgitation. J Thorac 
Cardiovasc Surg 140:1312-8.  
http://www.sciencedirect.com/science/article/pii/S002252231000036X 
9. Kalra K, Wang Q, McIver BV, et al. 2014. Temporal changes in interpapillary muscle 
dynamics as an active indicator of mitral valve and left ventricular interaction in ischemic 
mitral regurgitation. J Am Coll Cardiol 64(18):1867-79. 
10. Katoh T, Ikeda N, Nishi K, et al. 1999. A newly designed adapter for testing an ex vivo 
mitral valve apparatus. Artificial Organs 23:920–3. 
11. Kono T, Sabbah HN, Rosman H, Alam M, Jafri S, Goldstein S. 1992. Left ventricular shape 
is the primary determinant of functional mitral regurgitation in heart failure. J Am Coll 
Cardiol 20:1594–1598. 
http://www.sciencedirect.com/science/article/pii/073510979290455V 
12. Kumanohoso T, Otsuji Y, Yoshifuku S, et al. 2003. Mechanism of higher incidence of 
ischemic mitral regurgitation in patients with inferior myocardial infarction: quantitative 
analysis of left ventricular and mitral valve geometry in 103 patients with prior myocardial 
infarction. J Thorac Cardiovasc Surg 125:135–43.  
http://www.jtcvsonline.org/article/S0022522302733254/abstract 
 48 
13. Kwan J, Shiota T, Agler DA, et al. 2003. Geometric differences of the mitral apparatus 
between ischemic and dilated cardiomyopathy with significant mitral regurgitation real-time 
three-dimensional echocardiography study. Circulation 107:1135–40. 
http://circ.ahajournals.org/content/107/8/1135 
14. McGee J, Edwin C, Gillinov AM, et al. 2004. Recurrent mitral regurgitation after 
annuloplasty for functional ischemic mitral regurgitation. J Thorac Cardiovasc Surg 
128:916–24. 
http://www.sciencedirect.com/science/article/pii/S0022522304011432 
15. Monnet E and Pouching K. 2013. An ex vivo model of left ventricular dilation and functional 
mitral regurgitation to facilitate the development of surgical techniques. The Heart Surgery 
Forum 16(6): 332-38. 
16. Otsuji Y, Levine RA, Takeuchi M, Sakata R, Tei C. 2008. Mechanism of ischemic mitral 
regurgitation. J Cardiol 51:145–156. 
http://www.sciencedirect.com/science/article/pii/S0914508708000877 
17. Perloff JK, Roberts WC. 1972. The mitral apparatus functional anatomy of mitral 
regurgitation. Circulation 46:227–239. 
http://circ.ahajournals.org/content/46/2/227 
18. Richards AL, Cook RC, Bolotin G, Buckner GD. 2009. A Dynamic Heart System to 
Facilitate the Development of Mitral Valve Repair Techniques. Ann Biomed Eng 37:651–60. 
19. Sabbah HN, Kono T, Rosman H, Jafri S, Stein PD, Goldstein S. 1992. Left ventricular shape: 
A factor in the etiology of functional mitral regurgitation in heart failure. Am Heart J 
123:961–966. 
http://www.sciencedirect.com/science/article/pii/000287039290703X 
20. Siefert AW, Rabbah JPM, Koomalsingh KJ, Touchton SA Jr, Saikrishnan N, McGarvey JR. 
2013. In vitro mitral valve simulator mimics systolic valvular function of chronic ischemic 
mitral regurgitation ovine model. Ann Thorac Surg 95:825–30. 
http://www.sciencedirect.com/science/article/pii/S0003497512026045 
21. Tibayan FA, Rodriguez F, Zasio MK, et al. 2003. Geometric distortions of the mitral 
valvular-ventricular complex in chronic ischemic mitral regurgitation. Circulation 108:II–
116–II–121.   
http://circ.ahajournals.org/content/108/10_suppl_1/II-116 
22. Uemura T, Otsuji Y, Nakashiki K, et al. 2005. Papillary muscle dysfunction attenuates 
ischemic mitral regurgitation in patients with localized basal inferior left ventricular 






5. EVALUATION OF THE EFFECT OF THE THREE-DIMENSIONAL GEOMETRY OF 
THE LEFT VENTRICLE ON THE SEVERITY OF MITRAL REGURGITATION VOLUME 
IN AN EX VIVO PULSATILE MODEL OF LEFT VENTRICULAR DILATATION WITH 




Functional ischemic mitral regurgitation is associated with complications and poor 
prognosis,1,18 which is independent from ventricular function.9 Ring annuloplasty is currently 
used as the method of choice to treat FIMR.3,10,29 Although short-term studies reported 
satisfactory outcomes of this technique,2,5,24 higher than 20% in late recurrence of FIMR and 
ongoing LV remodeling has been observed.4,6,11,14,20,22,26 Posterior papillary muscles  
displacement and continued LV remodeling were the predictors of FIMR recurrence after ring 
annuloplasty.11,19 Therefore, to achieve optimal surgical strategies for FIMR treatment, the 
mechanism of FIMR needed to be thoroughly investigated. Studies in human and animal models 
have focused on two main components that associated with FIMR including dilatation of mitral 
annulus and displacement of the PPM.13,17,27,30  
 Augmentation of the interpapillary distances and PPM tethering distances from the 
anterior mitral annulus have been frequently reported in clinical patient with FIMR or research 
model of FMR.15,25,27,28 Those measurements were completed on a two-dimensional (2D) plane.  
The outward displacement of the PPM would be better evaluated in three-dimensional (3D) 
plane.  Therefore a XYZ coordinated displacement of the PPM would be better understood 
which could bring some light on the treatment of the FMR.  
Three dimensional echocardiography and 3D cardiac MRI were used as non-invasive 
techniques for clinical studies or research settings to have a better understanding of the tethering 
 50 
during FIMR or after annuloplasty.12,15,16 Annular height, commissural width and non-planarity 
angles have been evaluated in patients with FMR and before and after annuloplasty.19,21 Those 
3D evaluations were limited to the mitral leaflet and were difficult to apply to the entire mitral 
apparatus in clinical patients and animal models. Piezo-electric crystals for sonomicrometric 
analysis could provide precise 3D geometric evaluations.27 These techniques were invasive 
which made it inappropriate for clinical studies.  An ex vivo model of FMR allow evaluation of 
the geometric changes inducing FMR in a 3D plane. 
The purposes of this study were to use sonomicrometry in an ex vivo heart model to 
evaluate the tethered distances and tethered angles of the PPM due to regional LV dilatation. We 
aimed to identify the geometric changes that were associated with the development of FIMR 
despite normal mitral annulus. The experiments were conducted in ex vivo pulsatile model of 
FIMR with normal mitral annulus seen in recurrence of FIMR after ring annuloplasty cases. We 




5.1. Material and methods 
5.1.1. Model Preparation 
Fresh ovine hearts with no cardiac abnormalities were collected from sheep euthanized 
for reason unrelated to this study, stored at 4°C and the experiments were carried out within 24 
hour. A reversed “U”-shaped incision was made around the PPM without damaging the chordae. 
The PPM remained intact with a 2 cm strip of myocardium at the apical LV wall. Three sizes of 
crescent-shaped diaphragmatic patches were chosen to suture close the incision made around the 
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PPM. The patches were respectively 1 (small), 2 (medium), and 3 (large) centimeters wide at 
their widest point. The hearts were randomly assigned to one of the following group: small, 
medium and large group.  This created a focal dilatation of the LV and displacement of the PPM. 
Six piezo-electric crystals (2 mm round piezo-electric crystal, Sonometrics Corp., 
London, Canada) were placed within the LV wall.  Regional wall motion and distances between 
piezo-electric crystal pairs were measured continuously with a data acquisition system 
(SonoSoft, Sonometrics Corp., London, Canada).  
The ex vivo dynamic hearts were connected to a dynamic pressurization system (Bio-
console 520D Centrifugal Blood Pump, Bio Medicus, Minnesota) (Figure 5.1). The dynamic 
pressurization system generated pulsatile flow with a cannula introduced in the apex of the LV.22 
Pulsatile flow was simulated with a flow of 4 liter per minute and 40 beat per minute with the 
flow traveling from the apex of the LV into the aorta. The maximum left ventricular pressure 
(LVPmax) was maintained between 85- 120 mmHg. An aortic outflow valve could be adjusted to 
decrease or increase outflow resistance until LVPmax reached desired value. A cannula placed in 
one of the pulmonary vein was used to measure the volume of MR per minute.  The cannula was 
placed 15 cm above the mitral valve. A high-fidelity pressure transducer (Millar, Inc., Houston, 
USA) was inserted into the LV in a retrograde fashion via the aorta to measure LVP. Each 
treatment was observed whether regurgitation occurred or not. The MR volume flow rate was 
measured in milliliter per minute in heart with MR. The hearts after patch placements were 
categorized into 2 groups: hearts that produced MR volume (MR+ group) and hearts without MR 





Figure 5.1. Illustration of the heart model connected to the dynamic pressurization system. Black 
arrows indicated the fluid flow direction. 
 
 
5.1.2. Measurement of the PPM displacement relative to Cartesian coordinates 
Piezo-electric crystals 1, 2, 3 and 4 also served as markers for the best-fitted plane 
calculation. Data from these piezo-electric crystals were analyzed by a computer software 
(SonoXYZ, Sonometrics, London, Canada) and used to generate the Cartesian coordinates 
throughout the time course of an experiment. The piezo-electric crystal at the level of the fibrosa 
of the annulus was used as the origin for 3 positive (lateral, anterior, and apical) and 3 (medial, 
posterior, and basal) negative axes. These 6 axes were used for constructing 3 perpendicular 
planes: annular plane, frontal plane and sagittal plane (Figure 5.2). The positive lateral axis (X 
axis) passes through piezo-electric crystal #2. The positive apical axis (Y axis), perpendicular 
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with the X-axis, is directed toward the apical piezo-electric crystal #4. The positive anterior axis 
(Z axis), perpendicular with the X-axis and Y-axis, was calculated by the computer software 
(SonoXYZ, Sonometrics, London, Canada) directed toward the annular anterior commissure 
piezo-electric crystal #3. The 3D PPM positions at LVPmax were determined into their X, Y and 
Z coordinates. Position of the PPM to the fibrosa was recorded in the lateral, anterior, and apical 
axis. Displacement of PPM in the lateral, anterior and apical axes were calculated with the 
following formula:  (Distance of PPM to Fibrosa after placing patch) – (Distance of PPM to 
Fibrosa at Baseline).  
 
5.1.3. PPM tethered angle measurements relative to Cartesian coordinates 
The PPM tethering angles referred to the mitral annulus were evaluated with the angle α 
and angle β. The α and β angles at LVPmax were measured and calculated referring to the 
Cartesian coordination planes. Given that α is the angle formed by positive X axial segment and 
fibrosa-PPM tip segment. The β angle is formed by positive X axial segment and lateral annulus-
PPM tip segment (Figure 5.3).  The changes of the α and β angles from baseline were evaluated 
in the annular plane (αa and βa angles) (Figure 5.3A) and frontal plane (αf and βf angles) 
(Figure 5.3B). 
 
5.1.4. Statistical analysis 
Analyses were performed with SAS version 9.4 (SAS Institute Inc). Data was report as 
mean ± SD and statistical significances were considered when P<0.05. A paired t-test was used 
to compare continuous data between baseline and after application of the patch. Relative change 
values were compared between the MR(+) group and MR(-) group with Student’s t-test. Relative 
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change values, calculated by the differences between the treatment and baseline value divided by 
the baseline of each heart model. Multivariate regression analysis based on stepwise model 


























Figure 5.2. Best-fit Cartesian plane calculated from the SonoXYZ software using piezo-electric 
crystals 1, 2, 3 and 4 as a reference marker. The lateral, anterior and apical axes are labeled as 
black arrows pointing in the positive direction. Piezo-electric crystals placed in the LV are 























Figure 5.3. Illustrates 6 transducers placement and PPM tethered angles in the annular plane and 
frontal plane. The numbers marked the landmarks of the transducers. The angles were marked as 
α and β. Transducer 1, 2, 3 and 4 were used as reference to construct Cartesian planes. (A) 





Twenty-two ovine hearts, from the initial pool of 36 hearts, were entered in the study. 
Fourteen hearts were rejected because of leakage around the sutured patch, failure to generate 
significant LVP and atrial puncture. Eleven hearts developed MR and were entered in the MR+ 
group. Two hearts were in the small patch group, 2 were in the medium patch group, and 7 were 
in the large patch group. Eleven were entered in the MR- group. Five hearts were in the small 
patch group, 5 were in the medium patch group, and 1 was in the large patch group. Left 
ventricular volume increased significantly after applying the patches from 25.9±12.0 ml at 
baseline to 38.3±21.2 ml after applying a patch, (P=0.049) in the MR + group and from 
B. A. 
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24.1±13.3 ml at baseline to 29.0±14.3 ml (P=0.002) in the MR- group. The LVV after placement 
of the patch were not significantly different between the MR+ and MR- groups (P=0.207). Mitral 
annular septo-lateral dimension, commissural-commissural dimension and mitral annular area 
were not significantly different from baseline and between the two MR groups (P>0.05). 
Distances of the PPM tip from different anatomical landmarks measured at baseline and 
after patch application were reported at LVPmax for the MR+ and MR- groups (Table 5.1). In 
both MR+ and MR- groups, the distances of fibrosa to PPM and interpapillary muscle tips 
increased significantly compared to baseline. Using the Cartesian planes, lateral displacement of 
the PPM was significantly greater in both MR+ and MR- groups. Displacement of the PPM in 
the lateral axis increased from baseline 8.7±7.8 mm (P=0.007) for the MR+ group and 7.5±6.8 
mm (P=0.004) for the MR- group (Figure 5.4). No significant changes in the PPM displacement 
in the apical and anterior direction were noted in both groups.  
In MR+ group, the application of the patch significantly reduced the αf angle from 45.3 
±6.6° at baseline to 35.9±8.8° (P<0.05).  The angle αa was not significantly changed when 
compared to baseline (8.5±11.8° vs 6.4±8.0°, P>0.05). Figure 5.5 showed βa and βf angles were 
not significantly changed when compared to baseline (116.4±64.0° vs 136.2±59.8° and 
104.9±20.4° vs 102.3±14.9, P>0.05 respectively).  
In the MR+ group, the amount of MR volume was better determined by a model 
including the interpapillary muscle distance, lateral axial displacement of the PPM tip, tethering 
αa angle and the tethering βf angle (P<0.05). Basic descriptive statistics and regression 
coefficients are shown in Table 5.2. The estimated regression equation for the multiple 
regression of MR volume = 1674.77 + 89.25 (Interpapillary distance) + 69.08 (Lateral axial 
displacement) – 63.73 (αa angle) + 105.66 (βf angle) (P=0.008, R2 = 0.83). 
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Table 5.1. Distance measured from different landmarks to the posterior papillary muscle before 













Distance referred to 
anatomical landmarks 
    
    Fibrosa to PPM, mm 50.41±4.01 56.77±7.28* 50.45±6.85 54.29±6.09* 
    Lateral to PPM, mm 36.15±3.61 34.91±3.13 36.28±8.62 35.11±7.22 
    Interpapillary, mm 20.31±7.39 26.36±7.58** 19.11±3.71 25.14±5.00* 
Distance referred 3-D axes 
(using fibrosa as origin) 
   
    Lateral axis, mm 37.83±6.30 46.48±9.52* 30.38±10.98 39.26±11.76* 
    Anterior axis, mm 4.93±7.44 1.11±13.50 8.38±14.39 2.58±6.62 








Table 5.2. Multiple regression model with four explanatory variables 
 
Variable Coefficient (β) SE P-Value 95% CI 
Intercept 1674.774 1108.64   
Interpapillary distance 89.249 30.09 0.031 11.91-166.59 
Lateral axial displacement  69.077 17.43 0.011 24.26-113.89 
αa angle -63.725 10.08 0.002 (-89.64) - (-37.81) 
βf angle 105.655 20.80 0.004 52.18-159.13 










*    = P-value < 0.05  vs. Baseline 






















Figure 5.4. Three-dimensional displacement of the ppm within the lateral, apical and anterior 
axis in (A) MR+ and (B) MR- heart model groups; * indicates significant PPM displacement 





A. Frontal Plane             B. Frontal Plane               C. Annular Plane                 D. Annular Plane     
   MR (+)       MR (-)                 MR (+)           MR (-) 
 
 
Figure 5.5. Tethering angles of the PPM tips referred to fibrosa (α) and lateral (β) annular 
landmarks measured in frontal plane of MR+ group, Frontal Plane of MR- group, Annular plane 
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Three-dimensional evaluation of the geometry of the LV associated to FMR was possible 
with piezoelectric crystals in an ex-vivo model of FMR. It showed that not only the lateral PPM 
displacement and the interpapillary muscles were important parameters for the development of 
FMR but the tethering angle of the PPM was also an important parameters during the 
development of FMR. 
In our model we selectively displaced the PPM to induce an asymmetrical distension on 
the mitral valve leaflet and annulus. Gorman and colleagues7 showed a dis-coordination between 
the anterior and the posterior papillary muscle contributes to FMR.  This discoordination result 
in asymmetrical traction on the mitral valve leaflets.15  
Most of the studies related to FIMR have looked at interpapillary muscles distance and 
distance from different points on the mitral annulus to the PPM and documented an increased in 
tethering as a cause of FIMR following myocardial infarction.11,12,22,32 We reported similar 
changes in our ex vivo model. Lateral displacement of the PPM in FIMR studies were also 
reported in animal models.15,27 Three-dimensional MRI has been used in a porcine model of 
FIMR to study the remodeling related to FMR.15 The PPM was displaced posteriorly and the 
interpapillary muscles distance increased in their porcine model of FIMR.  
Using 3D evaluation of the geometry of the LV, the tethering angle of the PPM in the 
frontal plane was identified as a factor responsible for the development of FMR. The angle in the 
frontal plane decreased while the PPM was displaced.  The reduction of the α angle in the frontal 
plane in the construct that developed MR was due to upward displacement of the PPM closer to 
the lateral annulus. This was also found in 3D geometric study of acute and chronic FIMR ovine 
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model.7,27 Tethered distance of the PPM tip outside the lateral annulus from both LV remodeling 
and relative to mitral annuloplasty could restrict the posterior mitral leaflet.8,12   
In two different studies in an attempt to evaluate PML tethering in FIMR, a similar angle 
was evaluated before and after annuloplasty and after recurrence.19,31 However they only used 
2D echocardiography which makes the comparison with our study difficult.  In their study the 
tethering angle was reduced after restrictive annuloplasty and increased with recurrence.  
However the variation of this angle was similar in groups with or without recurrence of mitral 
regurgitation. Measurement of the angle during 2D echocardiography can be very operator 
dependent. In our study with evaluation in three different Cartesian planes, the α angle in the 
frontal plane decreased with development mitral regurgitation.   
The tethering α angle of the PPM measured in the annular plane was not significantly 
increased however it showed a slight increase in the MR(+) group which was not present in the 
MR(-) group.  This may relate to the posterior displacement of the PPM. The tethering α angle of 
the PPM in the annular plane was a factor for the development of mitral regurgitation in our 
multivariate regression model.  Reduction of this angle was associated with an augmentation of 
mitral regurgitation. The reduction of the tethering α angle in the annular plane resulted in 
distortion of the mitral valve apparatus which resulted in FMR. Distortion of the mitral valve has 
been shown to induce FIMR in an acute situation.7 Distortion was the result of upward and 
centroid displacement of the tip of the PPM as reported in this study.  Reduction annuloplasty 
has been shown to alter the geometry of the leaflet apparatus by placing the PPM outside of the 
annulus in a 3D projection.12 The displacement of the PPM outside the mitral annulus should 
further decrease the tethering α angle of the PPM in both the frontal and annular planes. This 
could be one explanation for a high recurrence rate after reduction annuloplasty. 
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The tethering β angle in the frontal plane was not significantly affected before and after 
applying the patch.  However it was a significant parameter in multivariate regression model.  
Augmentation of this angle would result in a more severe mitral regurgitation.  Similar results of 
the tethered angle of PML have been shown in a study evaluating recurrent MR after surgical 
annuloplasty.19 Patients that experienced a recurrent FMR had an increased in their tethering 
angle of the PML. Also, the restrictive annuloplasty by moving the entire mitral annulus toward 
the fibrosa will increase this angle and more likely contributing to recurrence.12  
The model developed in this study demonstrated that the development of FMR is 
multifactorial.  The four independent variables included in the model were able to explain 83% 
of the MR volume. The interpapillary muscle distance, lateral axial displacement of the tip of 
PPM, and the tethering angle of the β angle in the frontal plane had significantly positive 
regression effects, indicating that heart with higher values of these measurements were expected 
to produce higher volume of MR. Meanwhile, the tethering α angle in the annular plane had a 
significantly negative effect on the MR volume, indicating that after constantly controlling other 
measurements, hearts with larger tethering α angle in the annular plane was expected to produce 
lower MR volume.  
This study has several limitations. Functional mitral valve regurgitation was induced with 
only PPM displacement without mitral annular dilatation in ex vivo heart models. This study 
mimicked clinical situations when patients had normal or undersized mitral annulus after mitral 
annuloplasty yet encountered persistent or recurrent FIMR post-annuloplasty from LV 
remodeling.11,12,22,31 This ex vivo model even being pulsatile did not reproduced the myocardial 
contractions during the cardiac cycle that affect the geometry of the LV and the anatomy of the 
mitral annulus. It mostly reproduced the aneurysmal dilation that occured after myocardial 
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infarction. Measurements were recorded at maximal pressure in the LV which was equivalent to 
the systolic pressure at the end of the isovolumetric contraction in the cardiac cycle. The small 
sample size of this study could have limited the power to detect the significant differences in 
relative change of the 3D displacement and the PPM tip angles referred to the annulus between 
the MR(-) and MR(+) groups. However, the purpose of this study was achieved by 
demonstrating significant tethered angle in the MR(+) group and also strong predictors for MR 
severity which included the tethered angles of the PPM tip from multivariate analysis. 
In conclusion, our study demonstrated that the tethered angle of the PPM tip along with 
interpapillary muscles tethered distance and lateral displacement of the PPM tip could be used to 
predict MR severity when measured in 3D Cartesian planes. This could be used to predict MR 
persistence/recurrence post-annuloplasty. Furthermore, it could be used to evaluate when PPM 
relocation was needed as an adjunctive treatment.   This ex vivo study showed the importance of 
a 3D evaluation of the geometry of the LV and outward displacement of the PPM after 
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6. EPICARDIAL PPM REPOSITIONING WITH MITRAL ANNULAR REDUCTION FOR 




Functional ischemic mitral regurgitation is associated with complications and poor 
prognosis after cardiac surgery.3,38 It is characterized by Carpentier type I and type IIIb 
functional classification.10 The mortality in coronary artery disease patients is related to the 
severity of FIMR, which is independently from ventricular function.24 Twenty-thirty percent, or 
as high as 59 percent,43 of the patients with myocardial infarction will encounter FIMR.7,9,11,16,41  
Despite mild mitral regurgitation, the risk of heart failure and mortality significantly increases 
compared to normal patients and the outcomes worsen with increased severity of 
FIMR.6,13,15,24,40,44,61 Regarding to normal mitral leaflet structures, FIMR is related to dilatation 
of the mitral annulus and restriction of the mitral leaflets during systole due to PMs 
displacement.  
FIMR is widely accepted as a “ventricular” problem.4 Papillary muscles displacement 
induced mitral valve tethering, which result in mitral regurgitation from the loss of normal 
coaptation of the leaflets. In addition to CABG, ring annuloplasty with or without reduction (or 
restricted mitral annuloplasty) is currently used as the method of choice to treat FIMR.46-48 The 
concept of ring annuloplasty is to bring the annular dimension closer together so that the mitral 
leaflets could completely form coaptation. This technique has given high successful rate in short-
term studies.4,11,55 Despite early satisfactory outcomes of this technique, late recurrence of FIMR 
has been observed in a significant number of cases.8,17,32,45 Post annuloplasty progression of LV 
remodeling and mitral valve tethering could impair outcomes from annuloplasty alone.26 Adjunct 
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procedures should be used to address the LV remodeling and prevent recurrence of FIMR after 
surgery.  
Since annuloplasty alone could not prevent late recurrent FIMR or improve the survival 
rate after CABG, therefore we hypothesized that epicardial repositioning of the PPM adjunct 
with mitral annular reduction would improve leaflet coaptation assessed by reduction of MR. We 
aimed to show how septo-lateral mitral annular reduction, overall papillary muscle tethering 
distances, 3D PPM geometry, papillary muscle tethering angle and different methods of 
treatment influenced MR reduction. This study would demonstrate the feasibility of an epicardial 
correction to study geometric changes after mitral annular reduction alone compared to PPM 
repositioning adjunct with mitral annulus reduction in a pulsatile ex vivo heart model of FIMR. 
 
 
6.1. Material and methods 
6.1.1. The ex vivo hearts preparation  
Fresh ovine hearts from 36 adult Dorsett sheep (50±7 kg) with no cardiac abnormalities 
were collected and stored at 4°C. Experimentation was done within 24 hours. The hearts were 
prepared and MR was induced by annular dilatation and PPMs displacement as described in 
previous study from Monnet et al.52 An incision was made around the PPM without damaging 
the chordae to allow displacement of the PPM. The PPM remained intact with a 2 cm strip of 
myocardium at the apical LV wall. LV wall around the PPM was sutured closed with a 3 cm 
diaphragmatic patch; this creates a focal dilation of the LV wall and cause outward displacement 
of the PPM. Our previous study on the ex-vivo pulsatile heart model of functional mitral 
regurgitation had showed that the 3 cm diaphragmatic patch size placement induced the highest 
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heart models with MR and also produced the highest MR volume. From these data, the 3 cm 
patch was used to increase the length of the LV wall at the level of the PPM.  
In this study, we induced MR by both displacing the PPM away from the anterior mitral 
leaflet and increasing the septo-lateral annular dimension, mimicking LV remodeling and mitral 
annular dilatation in FIMR patients.31,56,65 The left atrium was incised to access the mitral 
annulus. The septo-lateral annular dimension was measured before inducing annular dilatation. 
The annular dilatation was achieved by mechanical stretch,59 without damaging the leaflet and 
chordae, in the septo-lateral direction until the diameter increased approximately 30 percent of 
the anterior mitral leaflet height.36,62,63 Studies have shown that annular dilatation in the septo-
lateral direction along with papillary muscle displacement can produce MR.22,33  
Six intracardiac 2 mm piezo-electric crystals (2 mm round piezo-electric crystals, 
Sonometrics, London, Canada) were sutured to 6 mitral apparatus landmarks (Figure 6.1). 
Crystal 1 was placed at the level of the fibrosa or septal part of the mitral annulus and Crystal 2 
was placed opposite side of Crystal 1 on the mid-lateral or lateral part of mitral annulus. Crystal 
3 was placed at the anterior commissure of the mitral annulus and Crystal 4 was placed at the LV 
apex. These 4 crystals were used for the calculation of the best-fitted plane for further geometry 
analysis. Crystal 5 was placed on the tip of the APM and Crystal 6 was placed on the tip of the 
PPM.12 Nine crystal pairs were of interest and used for the LVV calculation and analysis of the 
annular and papillary muscles geometry (Table 6.1). Regional wall motion and distances 
between crystal pairs were measured continuously with sonometric data acquisition system 
(SonoSoft, Sonometrics Corp., London, Canada). Three-dimensional (3D) coordination of each 
piezo-electric crystal was recorded at 200 Hz with simultaneous measurement of LVP.19,30  
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Figure 6.1.  Positions of the 6 piezo-electric crystals in the LV and mitral annulus. C1, C2, C3, 
C4, C5 and C6 represented the piezo-electric crystals 1, 2, 3, 4, 5 and 6 respectively. AML, 
anterior mitral leaflet; PML, posterior mitral leaflet; APM, anterior papillary muscle; PPM, 
anterior papillary muscle. 
 
 
Table 6.1. Piezo-electric crystal pairs used for tethered distance measurements and reference 
markers for Cartesian plane construction. 
Abbreviations: APM, anterior papillary muscle; PPM, anterior papillary muscle 
Crystal pair Distance between mitral apparatus landmark 
1 and 2 Septo-lateral diameter of the annulus/ Lateral Axis/ Minor Axis I 
1 and 3 Anterior axis 
1 and 4 Apical Axis 
1 and 5 Fibrosa-APM tip distance 
1 and 6 Fibrosa-PPM tip distance 
2 and 5 Lateral annulus to APM tip distance 
2 and 6 Lateral annulus to PPM tip distance 
3 and 4 Major Axis 
5 and 6 Interpapillary muscle distance/ / Minor Axis II 
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Two suture markers were placed on the epicardium to locate APM and PPM bases. After 
piezo-electric crystals placement, the left atrium and diaphragmatic patch were sutured closed. 
Figure 6.2 demonstrates the heart model connected to the pulsatile pressurization system. We 
used the same settings as in the previous chapter. The heart was mounted on a pulsatile 
pressurization system (Bio-console 520D Centrifugal Blood Pump, Bio Medicus, Minnesota), 











Figure 6.2.  FIMR heart model connected to the dynamic pressurization system. The black 
arrows indicated the flow direction. 1, reservoir tank; 2, pump generator; 3, pulsatile flow 
generator; 4, pressure transducer. 
 
 
The LVPmax was maintained at 120±5 mmHg. There was an aortic outflow valve that 
could be adjusted to decrease or increase outflow resistance until LVPmax reached desire value. 
Pulsatile flow was set at 4 liters per minute, 40 beats per minute with the flow traveling from the 
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LV apex into the aorta. If MR occurred, the MR flow will be collected and measured from the 
pulmonary vein cannula. A high-fidelity pressure catheter (Millar, Inc., Houston, USA) was 
inserted into the LV in a retrograde fashion via the aorta. It was used for LVP measurement 
throughout the experiment. 
The hearts were randomly assigned into 2 groups depending on the method to 
lower/eliminated MR; Septo-lateral mitral annular reduction (MA) group and PPM repositioning 
adjunct with septo-lateral mitral annular reduction (MA+PPM) group.  
 
6.1.2. Epicardial correction   
In this study, we adapted an epicardial apparatus to alter PMs positions without changing 
annular dimension. The epicardial apparatus in our study consisted of 4 main parts, 2 cross bars 
and 2 papillary muscles vertical bars (Figure 6.3A). The vertical bars had a retractable pushing 
pads that were placed on the epicardium at the level of the base of the APM and PPM. In this ex-
vivo study, we only adjust the retractable pushing pad at the PPM level. This pad was placed on 
the epicardium and aimed to push the PPM in a baso-medial direction toward the septal saddle 
horn of the annulus. Once the PPM vertical bar was placed at the desire position, the proximal of 
the vertical bar was secured with two mattress sutures apical to the atrioventricular groove and 
the distal part was secured at the apex. Care must be taken while placing the apparatus to avoid 
coronary vessels. The first cross bar was used to connect the distal portion of the vertical bars. 
The second cross bar was connected between the proximal portions (Figure 6.3B). The length of 
the proximal cross bar could be adjusted to reduce the annular septo-lateral dimension.  
After application of epicardial apparatus, the ex vivo heart was observed whether MR 
occurred or not. In the MA group, the proximal cross bar length was only adjusted until the 
maximum reduction, trace or no MR was achieved. In MA+PPM group, the proximal cross bar 
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length was adjusted until the maximum reduction of MR occurred then the vertical bar pushing 
pad at the level of PPM was adjusted to gain further maximum MR reduction. Hearts that failed 
to reproduce MR at baseline or failed to reduce MR after epicardial apparatus placement were 

















Figure 6.3. The epicardial device used for mitral annular dimension reduction and PPM 
repositioning. (A) Papillary muscles vertical bar (a) and the cross bar (b). The white arrow 
indicates retractable pushing pad. (B) Mounted epicardial device on the LV. The white arrow 




6.1.3. Data acquisition 
 Figure 6.4 showed the flow chart of the hearts that were included and excluded from the 
study. Data were collected into 2 groups determined by the treatment method used for MR 
reduction/elimination.  
Figure 6.3(A)                    Figure 6.3(B) 
    a.                            b. 
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6.1.3.1. Geometry analysis 
Data of the crystal pair distances were collected from each treatment group. Annular and 
papillary muscles geometry were analyzed at LVPmax, which represents the systolic phase when 
mitral valve closure occurs. Distances between crystal pairs were averaged over 10 pump cycles. 
Baseline data (Control) for each observation was collected before applying the LV epicardial 
contouring system and were used as its own control.  
Three-dimensional assessments of the papillary muscles tip displacements were evaluated 
using Cartesian planes at LVPmax. The 3D planes were defined by the best-fitted plane using four 
piezo-electric reference crystals (Crystal 1, 2, 3 and 4). Data from these crystals were analyzed 
by SonoXYZ software (Sonosoft, Sonometrics, London, Canada) to calculate the Cartesian 
coordinates throughout the time course of the experiment. We used the same method as in the 
previous chapter to construct the annular plane (XZ planar), frontal plane (XY) and antero-
posterior plane (YZ planar). The XZ, XY and XZ Cartesian coordinate planes were 
perpendicular to one another. The crystal at the level of the anterior annulus (C1) was use as the 
origin of 3 perpendicular vector axes.31 The positive lateral axis (+X) passes through the mid-
lateral annular crystal (C2). The positive apical axis (+Y), perpendicular with the lateral axis, 
was directed toward the apical crystal (C4). The positive anterior axis (+Z), perpendicular with 
the lateral axis and apical axis, was calculated by SonoXYZ software directed toward the annular 
anterior commissure crystal (C3). The APM and PPM positions at LVPmax were determined into 
their septo-lateral (X), antero-posterior (Z) and baso-apical (Y) components.  
The tethered degree of angle (α or β) of the AMP and PPM tips, reflecting restriction 
from displaced PPM and annular dilation, were evaluated. The angles were calculated in the 
annular and frontal planes using the same method as mention in the previous chapter (Figure 
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6.5). The α angle of the PPM was defined as the angle across the PPM tip. It was form by C1-C2 
segment and C1-C6 segment. The α angle of the APM was defined as the angle across the APM 
tip, formed by C1-C2 segment and C2-C5 segment. The β angle of the PPM was form by C1-C2 
segment and C2-C6 segment. The β angle of the APM was form by C1-C2 segment and C1-C5 
segment. The tethered angles were compared to baseline and between the groups. 
 
6.1.3.2. Quantification of MR, left ventricular volume and mitral annular area analysis 
MR stroke volume (milliliters per beat) was quantified by direct measurements of MR 
volume that exceed from the pulmonary vein port. MR stroke volume above 5 milliliters per beat 
was considered significant. MR stroke volume was measured and averaged over 10 pump cycles. 
The percentage of MR reduction from baseline was calculated. In this study, we modified 
quantification of MR by the measurements of the MR stroke volume from the AHA/ACC 
guidelines46 and Zoghbi et al. study.67 The MR severity was graded on a scale of 0 to 4, in which 
0 = no to trace MR (MR <5 ml/beat), 1 = mild (MR 5-20 ml/beat), 2 = moderate (MR 20-30 
ml/beat), 3 = moderate to severe (MR 30-40 ml/beat) and 4= severe (MR > 40 ml/beat.  
The LVPmax resembled the systolic phase in the normal cardiac cycle when the mitral 
valve was closed. MR should occur in this phase if there were mal-coaptation of the leaflets. Left 
ventricular volume was obtained and calculated by sonometric data acquisition system 
(CardioSoft, Sonometrics Corp., London, Canada) at LVPmax. The ‘Ellipsoid model’ equation 
was used for the LVV calculation. This model used three axes (Major axis, minor axis I and 
minor axis II). The distance between Crystal 1 and 2 was used as minor axis I. The distance 
between the anterior commissure of the annulus and the apex was used as major axis. The minor 
axis II was the axis between the tips of APM-PMM.  
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EQUATION:   LVV = 
 � ∗ ����� ���� ∗ ����� ���� ∗ ����� ���� �� 6  
 
Mitral annular area (MAA) before and after treatment was compared. MAA was 
calculated with the following equation:  MAA = π (r1) (r2)/4; r1 is the diameter of the 
septo-lateral annulus and r2 is the inter-commissure diameter. After the experiment was 
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Figure 6.5. Illustrates the APM and PPM tethered angles in the annular plane and frontal plane. 
The numbers marked the landmarks of the crystal. The angles were marked as α and β. Crystal 1, 
2, 3 and 4 were used as reference to construct Cartesian planes. (A, C) Oblique annular plane at 







6.1.4. Statistical analysis 
Data were analyzed using SAS version 9.4 (SAS University Edition, Institute Inc., Cary, 
NC) with significance at P<0.05 or stated values. Relative percentage change from baseline was 
calculated for each variable. Shapiro-Wilk test for normality distribution was tested before 
analysis. Data with numeric results were presented as median and interquartile range (median 
[Q1, Q3]), since normality of the data was not achieved. Wilcoxon Sign-ranked test was used for 
comparison of the variables at baseline and after treatment methods. Percentage relative changes 
between MA and MA+PPM groups were compared using a Wilcoxon Rank-sum test. Spearman 
correlation coefficient was used to present association between MR reduction and geometric data 




Left ventricular volume, MAA, and MR are reported in Table 6.2. Mitral annular area 
significantly decreased from baseline in the MA group (P=0.004). LVV significantly decreased 
in MA (P=0.02) and MA+PPM (P =0.01) groups when compared to its own baseline. MR 
severity grade significantly decreased from baseline in both MA (P =0.03) and MA+PPM groups 
(P =0.02). However, MA+PPM group did not significantly have MR grade and MR reduction 
lower than MA group (Table 6.2).   
The overall tethered distances and 3D displacement of the papillary muscles are reported 
in Table 6.3. The septo-lateral mitral annular distance significantly decreased after applying both 
methods (MA group P=0.005; MA+PPM group P=0.05). The tethered distances of the fibrosa to 
PPM tip and the interpapillary muscles significantly decreased from baseline in MA+PPM 
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groups (P=0.02 and P=0.047 respectively). The tethered distances of the fibrosa to APM tip 
significantly increased from baseline in the MA+PPM group (P=0.002). However, there were no 
statistically significant differences of the septo-lateral mitral annular distances and geometry of 
the papillary muscles tethered distances found between the 2 groups.  
The tethered angles of the papillary muscles referred to the septo-lateral mitral annular 
segment are reported in Table 6.3. The tethering α angle of the APM in the frontal plane 
significantly increased from baseline in the MA+PPM group (P=0.027). Furthermore, the 
MA+PPM group had a larger APM and PPM α angle in the frontal plane compared to the MA 
group after reducing the MR (P=0.04). There were no statistically significant changes in 
tethering angles found in the MA group compared to baseline.  
 When including all hearts with MR reduction after applying treatment methods, the 
percentage of MR reduction correlated with percentage decrease of septo-lateral mitral annular 
distance (rs=0.51, P =0.01), the percentage decrease of fibrosa-PPM distance (rs=0.43, P =0.03) 
and the percentage increase of the PPM anterior displacement (rs=-0.41, P =0.04) (Figure 6.6). 
We further studied how the septo-lateral mitral annular distance, fibrosa-PPM distance and PPM 
anterior-posterior displacement independently influenced MR reduction. To better understand 
how these 3 measurements influenced MR reduction, we divided the hearts based on the tertiles 
of the percentage of septo-lateral mitral annular relative distance reduction, percentage of 
fibrosa-PPM relative distance reduction and percentage displacement of PPM in the anterior-
posterior axis. They were defined by the magnitudes of the septo-lateral mitral annular relative 
distance reduction; the first (lowest) tertile included septo-lateral mitral annular relative distance 
reduction lesser than 0.8%, the second (middle) tertile included septo-lateral mitral annular 
relative distance reduction between 0.8-14.45%, and third (highest) tertile included septo-lateral 
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mitral annular relative distance reduction greater than 14.45%. The fibrosa-PPM relative distance 
reduction; the first (lowest) tertile included fibrosa-PPM relative distance reduction lesser than 
0%, the second (middle) tertile included fibrosa-PPM relative distance reduction between 0-
6.54%, and third (highest) tertile included fibrosa-PPM relative distance reduction greater than 
6.54%. Lastly, for the relative displacement of PPM in the anterior-posterior axis; the first 
(lowest) tertile included relative displacement of PPM in the anterior-posterior axis lesser than -
7.75%, the second (middle) tertile included relative displacement of PPM in the anterior-
posterior axis between -7.75-225%, and third (highest) tertile included relative displacement of 
PPM in the anterior-posterior axis greater than 225%. The positive values for the relative 
displacement of PPM in the anterior-posterior axis indicate anterior displacement and negative 
values indicate posterior displacement. 
Table 6.4 summarized the MR reduction in tertiles of septo-lateral mitral annular 
reduction, fibrosa-PPM reduction and PPM anterior-posterior displacement. Wilcoxon rank sum 
test was used for comparison between MA and MA+PPM groups. As a result, MR reduction in 
the first tertile of septo-lateral mitral annular reduction was significantly higher in the MA+PPM 
group.  
Figure 6.7 suggested that there were thresholds for the influences of septo-lateral mitral 
annular reduction with MR reduction. Wilcoxon rank sum test showed that the first tertile of 
hearts within the MA group had a significant lowest MR reduction (28[1.79,37.17] %) when 
compared with the second and third tertiles median and interquantile range (76.16[47.28,100] % 
and 100[89.61,100] %, respectively). MR reduction in the MA+PPM group was not significantly 
different between tertiles. MA+PPM group had significantly higher MR reduction in the first and 
second tertiles (79.22[64.10,100] % and 87.61[66.91,100] %, respectively) when compared with 
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the first tertile of the MA group (28[1.79,37.17] %). Figure 6.8 showed that the fibrosa-PPM 
reduction in second and third tertiles of both MA and MA+PPM groups have significantly higher 
MR reduction (47.28[39.71,76.16] %, 100[79.22,100] %, 75.85[64.10,100]% and 81.91[61.91, 
100] %, respectively) compared with the MA group first tertile (median and interquantile range, 
10[1.79,28] %). No significances were found between the tertiles and treatment groups in PPM 




Table 6.2. Data of the MR severity, MAA and LVV 
 
Values are in medians and interquartile ranges. MR, mitral regurgitation; MAA, mitral annular area; 
LVV, left ventricular volume. *Denotes P-value <0.05 versus Baseline. ¥ Relative change (%) after 
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Table 6.3. Tethered distances, 3D geometry and papillary muscles tethered angles. 
 
Values are in medians and interquartile ranges. *Denotes P-value <0.05 versus Baseline. ¥ Relative 
change (%) after epicardial device placement in MA+PPM versus MA group. APM, anterior papillary 
muscle; PPM, posterior papillary muscle; SL, septo-lateral; Fα, alpha angle in the frontal plane; Fβ, beta 
angle in the frontal plane; Aα, alpha angle in the annular plane; Aβ, beta angle in the annular plane.  
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Table 6.4. Comparison of the MR reduction between MA and MA+PPM groups for each tertiles 
of septo-lateral mitral annular reduction, fibrosa-PPM reduction and PPM anterior-posterior 
displacement.  
Values are in medians and interquartile ranges. MR, mitral regurgitation. NS, no significance found 






Figure 6.6. Scatter plots and Spearman correlation coefficient of MR volume reduction and left, 
SL annular distance reduction; middle, fibrosa-PPM distance reduction; right, PPM anterior 
displacement in percentages. In each subplot, rs is Spearman correlation coefficient. Scatter plots 
from MA group are marked as circles and MA+PPM group are marked as triangles.  
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Figure 6.7. Illustration of the severity of MR reduction in tertiles of the septo-lateral mitral 
annular reduction (relative distance reduction, %). *=P-value<0.05 vs MA group within the same 






















































Figure 6.8. Illustration of the severity of MR reduction in tertiles of the fibrosa-PPM reduction 
(relative distance reduction, %). *=P-value<0.05 vs MA group within the same tertile. Similar 





















































Figure 6.9. Illustration of the severity of MR reduction in tertiles of the PPM anterior-posterior 
axis displacement (relative distance reduction, %). *=P-value<0.05 vs MA group within the 
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6.3. Discussions 
Chronic FIMR, typically after posterior-lateral myocardial infarction, caused left 
ventricle (LV) remodeling.38 Although LV remodeling displaced both PMs (even the one which 
is not involved by the infarction) as the entire LV dilated; the APM displacement was minimal 
compared to the PPM. This event mainly caused asymmetrical PPM displacement at the LV wall 
where ischemia occurred.31,53 FIMR patients have restricted leaflet closure due to tethering force 
influenced by the displaced PMs and concurrent dilated annulus. Miller and colleague have 
showed that annular reduction in septo-lateral dimension was more significant in reducing MR.51 
Although the concept of ring annuloplasty was to bring the septo-lateral annular dimension 
closer together so that the mitral leaflets could completely form coaptation, surgical annuloplasty 
could also potentially increase PML tethering by relatively displacing the PPM outside the mitral 
annular ring.23,26,39 Despite excellent long-term results,25,39 recurrent FIMR and ongoing LV 
remodeling could be found post-annuloplasty.5,17  
The concept of reducing PMs tethering by combining subvalvular techniques to normal 
reduction annuloplasty was adapted by many researchers such as PMs relocation, trans-
ventricular suture technique, PMs approximation (PMA), chordal cutting and trans-ventricular 
devices.25,37,49,50,54,64 These techniques aimed to eliminate MR by reducing the tethered force on 
the mitral leaflets. Treatment of moderate to severe FIMR with annuloplasty alone seemed 
uncertain and the decision to add subvalvular technique depends on each individual case. 
Szymanski and colleagues64 showed that in chronic FIMR sheep models second-order mitral 
chordal cutting improved annuloplasty by reducing papillary muscle tethering. Similar results 
from a randomized clinical trial (the Papillary Muscle Approximation trial) the PMA in 
combined with reduction annuloplasty in severe FIMR showed better outcomes of adverse LV 
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remodeling and recurrent MR than the annuloplasty alone cases.54 Recent study compared 
patients with moderate to severe FIMR that had ring annuloplasty only versus patients that have 
had annuloplasty combined with subvalvular repair (PMs approximation or relocation or chordal 
cutting). At follow-up, the combined subvalvular repair group had reduced risk of mortality, 56% 
reduced risk of recurrent MR and significant LV remodeling.50 There was evidence that non-
restrictive annuloplasty adjunct with PPM displacement correction by PPM relocation in severe 
MR patients showed 97 percent freedom from recurrent MR grade 2 or greater at 5 years post-
operatively.14 PPM relocation and trans-ventricular suture techniques relied on sutures to relocate 
the PPM tip closer to the annulus. In theory, this created stress on the PPM tip and the annulus 
and could further lead to avulsion or suture breakage. Subvalvular techniques that reposition the 
whole body of PMs could help avoid the stress on the PMs tips and some part of the annulus 
such as PPM approximation60 and reversing LV remodeling with Dacron patch.27 LV remodeling 
with Dacron patch technique eliminated the need of cardiopulmonary bypass and atrial incision 
which could deteriorate surgical repair. The Dacron patch repositioned the PPM which was 
persistently effective in reducing moderate chronic IMR, even when LV volume increased. This 
can reflect structural stabilization by an external patch device of the papillary muscle-LV wall 
complex that controls mitral valve tethering.27  
The goal of our study was to evaluate a potential synergistic effect of the association of 
septo-lateral annular reduction with PPM repositioning. PPM repositioning via epicardial 
pushing pad at the level of the PPM should give information on how manipulating a single PMs 
could lower MR. This also introduced a further step in developing epicardial device which lessen 
the need of open heart surgery. Our study showed that the combined MA+PPM using the  
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epicardial adjustable apparatus directly repositioned the outwardly displaced PPM and reduced 
the MR without further compromising the MAA.  
The PPM in chronic FIMR was displaced more laterally in chronic FIMR sheep models.65 
They also found that the PML margin was displaced apically in chronic FIMR. Therefore to 
reduce MR, reversal of these geometric changes should be made. Although we did not see 
significant changes in the 3D PPM geometry after applying the MA+PPM group, our study 
revealed decreased of the fibrosa-PPM distance and the interpapillary muscle distance. This 
could indicate the baso-medial repositioning of the PPM tip. The interpapillary muscle distance 
was decreased after adjusting the PPM pushing pad to reduce/eliminate MR. Reduction of the 
interpapillary muscles distance should reduce the tethering force on the leaflets, especially 
improving the posterior leaflet mobility. Distance between the papillary muscles was a predictor 
for FIMR severity. Studies in both animal models and human patients have shown that the 
interpapillary muscle distance was associated with FIMR. Jensen and colleagues31 used porcine 
FIMR models and found that the interpapillary muscle distance was the only independent 
predictor for FIMR severity. A study in patients with chronic FIMR post CABG and reduction 
ring annuloplasty also showed that the pre-operative interpapillary muscle distance was 
associated with anterior mitral leaflet tethering, which was associated with recurrent FIMR.66 
Combined PPM reposition with annular reduction lowered PPM tethering which reduced 
tethering force on the leaflets, especially improving the PML mobility. In our study, the tethered 
length and angles of the PMs were measured instead of directly measuring from the mitral 
leaflets. We aim to demonstrate how manipulating the PPM via the epicardial can change the 
PPM geometry similar to extra-cardiac subvalvular techniques for FIMR treatment. These extra- 
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cardiac subvalvular techniques have been established to avoid CPB surgery which targeted on 
reducing the LV dilatation and interpapillary distance.1,2,57,58  
The reduction of the septo-lateral annular distance and the fibrosa-PPM distance had 
positive correlations with MR reduction in both treatment groups. The reduction degree of these 
parameters had different effects. Slight reduction of the septo-lateral annular distance in the 
combined treatment group significantly reduced MR. The MR reduction was nearly 3 times 
reduced in the combined group compared to MA alone group, when the SL annular distance was 
almost at the same size before treatment. This could be the effect of the PPM repositioning 
inwardly to lower the tethered force on the mitral leaflets. The various degree of septo-lateral 
annular reduction in the combined treatment group did not differ. They all showed signs of high 
MR reduction (>50%). On the contrary, aggressively reducing the septo-lateral annulus in the 
MA group did not show superior effect over combined treatment. Moreover, aggressive 
reduction of the mitral annulus could induce mitral stenosis.  
Tethered angle of the PMs were studied to help give us more information on the changes 
of the biomechanical mechanisms in heart models that reduced/eliminated MR after treatment. 
Adjustments of the epicardial pushing pad at the level of the PPM altered both mitral leaflets, 
since the PPM suspend both mitral leaflets. In Chapter 5, we found that the PPM frontal plane α 
angle decreased 10 degrees in hearts with MR. Therefore, increasing the PPM frontal plane α 
angle should reduce MR. In this study, the tethered frontal plane α angle of the PPM in the 
combined treatment group was relatively increased from baseline (15.83±33.34°) compared to 
MA alone group. This finding along with the decreased of the interpapillary muscles distance 
suggested that the PPM was repositioned inward and toward the septal annulus by the epicardial 
pushing pad. Our results demonstrated that combined PPM repositioning via the epicardial 
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apparatus associated with septo-lateral annular reduction in ovine heart models of FIMR setting 
improves MR as a result of improved coaptation and reduced interpapillary muscle distance. 
Although the ex vivo pulsatile heart model of FIMR produces annular dilatation and PPM 
geometric changes similar to previous studies of FIMR patients,20,21,42,63 limitations can be found 
in this study. The primary limitation of this study is that the heart model does not have functional 
myocardium. LVP and MR were generated by the pressurization of the dynamic pump system. 
Physiological function of the LV after device placement cannot be assessed such as the ejection 
fraction, LV elasticity and evaluation of the myocardial blood flow. Further concerns for 
myocardial blood flow alteration are focal ischemia of the LV myocardium initiate by the contact 
pressure from the pushing pads. Similar studies of epicardial device that apply pressure on the 
myocardial wall have not demonstrated focal ischemia from device placement in animal 
models.29,34,35  
From this study, we did not know exactly which tethered leaflet resolved after treatment 
since the PPM that was repositioned had chordae suspended to both leaflets. Leaflet tethering 
angles using 3D echocardiography with a standard reference system would assist further study 
on the leaflet 3D geometry. Another limitation of this study is the lack of validation on 
aggressive annular reduction. In our study we only adjust the proximal cross bar of the epicardial 
device to reduce the annular dimension until the maximum reduction of MR, trace or no MR was 
achieved. Although, we have found mitral stenosis in one observation with total MR elimination 
after MA treatment, but was excluded from the study. Aggressive annular reduction without 
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Developing new surgical tools and techniques for FIMR treatment required excessive 
testing and validation. Animal trials are normally used for standard testing but requires time and 
expenses. In the early stage of subvalvular adjunctive treatment development, it is best to 
conduct the experiment in an ex vivo pulsatile heart model of FIMR which is cost efficient, 
requires less time, reduce complexity and lessen the need of laboratory animal usage and 
sacrifice. 
The results of this dissertation have mechanistic and applicable implications. We have 
managed to develop an ex vivo pulsatile heart model for the purpose to study mechanistic of MR 
from LV dilatation and PPM displacement. The first phase of this study highlights that MR could 
occur without annular dilatation. MR could be simulated in heart models of LV dilatation and 
PPM displacement despite normal sized annulus. This could imply to clinical observations in 
FIMR patients where persistent or recurrent MR often occurred post reduction ring annuloplasty. 
The propose heart model was comparable to post-annuloplasty recurrent MR of FIMR cases 
where interpapillary muscle distance played an important part associating with MR severity.   
Although displaced distances of the PPM from anatomical landmarks and in 3D 
coordinate planes from baseline where not different between non-MR and MR occurring heart 
models, tethering α angle in the frontal plane in heart models with MR showed significant 
decrease when compared to baseline. This could be an indication that the tethered angles of the 
PPM tip referred to the annulus should be taken into consideration when treating FIMR, since 
tethered PPM affects both mitral leaflets. 
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In the past decades, studies have demonstrated an effective ex vivo heart model that 
mimicked FMR, but none were suitable for studying PMs displacement and validating 
subvalvular repair that required the continuity of the LV wall and the PMs.1-4 Most ex vivo heart 
models focused on the dilated annulus or developed the model in a cylinder chamber without the 
continuity of the PMs and LV wall. In contrast, our study targeted on developing an ex vivo heart 
model of FMR that have PMs attached to the LV. The ex vivo pulsatile heart model of FMR that 
we developed gave us the ability to directly measure the MR and precisely measure the mitral 
apparatus landmarks via sonomicrometry. The benefits from utilizing this ex vivo pulsatile heart 
model were 1) the ability to make further studies on the PPM repositioning strategies, 2) the 
procedure could be evaluate on a pseudo-beating heart model with pulsatile fluid flow which 
would allow us to continuously monitor the MR and mitral geometry. This would help determine 
how manipulating the mitral apparatus from different surgical repair strategies could change the 
mitral geometry and reduced MR and 3) the model could be applied for testing and validating the 
development of future epicardial treatment strategies for FIMR treatment strategies in the early 
stages of the design before using in animal and clinical trials.  
Subvalvular techniques to treat FIMR is a promising path especially in severe FIMR 
cases when reduction annuloplasty alone causes further LV-mitral valve ring mismatch. The last 
phase of this research showed that subvalvular epicardial corrections could be done to correct the 
mitral annulus and the displaced PPM. The study showed that annular reduction and the 
combined PPM relocation with annular reduction both significantly reduced MR. Lowering the 
septo-lateral distance, fibrosa to the PPM distance, and PPM posterior displacement after 
treatment were associated with MR reduction. The combined treatment group had significantly 
reduced MR even with slightly reduced annular size.  
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Transcatheter mitral repair and LV devices are being developed to deploy in a beating 
heart to avoid the requirement of assisted-CPB which lessen the CPB time. These minimally 
invasive techniques could give profound results especially in some patients that were not good 
candidates for CABG. In patients with ischemic coronary artery disease, CABG alone usually 
takes 1-3 hours depending on the number of grafts and the CPB time could increase with 
complications. CPB procedures that exceed 3 hours are related to increased postoperative 
complications and mortality.5 Treatment for FIMR is challenging, since the full mechanisms is 
not completely understood.  Many researches focused on finding the preoperative and post-
operative cut-offs for determining the appropriate treatment for FIMR patients. The remaining 
questions include how to select patients that would benefit from reduction mitral annuloplasty 
and whether subvalular techniques would add better balanced to the mitral leaflets. This 
knowledge must be solved to find the best possible treatment tailored for each patient. Further 
studies on how the tethered PPM angle associated with each mitral leaflet geometry could 
provide better understanding. Moreover, this could provide further cut-off values when 
determining patients that would have mitral leaflets tethering after reduction annuloplasty that 
would need additional subvalvular repair. A standard reference system is important for interpret 
values between studies. Leaflet tethering angles using 3D echocardiography with a standard 
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AML  Anterior mitral leaflet 
APM  Anterior papillary muscle 
CABG  Coronary artery bypass grafting 
CPB  Cardiopulmonary bypass 
CVS  Cardiovascular  
FIMR  Functional mitral regurgitation 
FMR  Functional mitral regurgitation 
LV  Left ventricle/ventricular 
LVP  Left ventricular pressure 
LVV  Left ventricular volume 
MR  Mitral regurgitation 
PMA  Papillary muscle approximation 
PML  Posterior mitral leaflet 
PMs  Papillary muscles 
PPM  Posterior papillary muscle 
2D  Two dimensions 
3D  Three dimensions 
 
 
